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INTRODUCTION 
 
 Atherosclerotic vascular diseases, which comprises coronary heart disease and 
cerebro-vascular disease is a major global health burden. They constitute 21.9 per cent of 
total deaths globally and are projected to increase further to 26.3 per cent by 2030
1
. 
The prevalence of diabetes is a global health burden. The overall prevalence is 
expected to rise from 285 million in 2010 to 438 million by the year 2030
2
. While diabetes 
poses a huge economic burden to all nations, developing countries bear the highest burden 
since more than 80% of cases occur in these countries.
 
Diabetes is considered as an independent risk factor for coronary artery disease and 
cardio vascular diseases. As per NCEP ATP III guidelines, diabetes is considered as a 
coronary artery disease equivalent
3
. 
Diabetes affects the endothelium and the glycation products get denatured and 
accelerate the process of atherosclerosis. Diabetic patients when compared to non-diabetics 
have increased risk of developing vascular complications and have two to four fold risk of 
developing coronary artery disease (CAD)
4
. They are more likely to develop vascular 
complications, affecting all the major organs of body. Cardiovascular diseases constitute one 
of the major cause of mortality and morbidity in diabetics, accounting for nearly 65-75% of 
deaths
5,6
. 
 
The results of Framingham study reveals a 2 fold risk of cardiovascular death in men 
and 4-5 fold risk of cardiovascular death in women with diabetes. They constitute the major 
cause of death in adult diabetic patients. Diabetics are likely to have low HDL levels than 
people without DM. Low HDL levels have been strongly associated with elevated risk for 
CAD. 
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 Nearly 75% to 80% of deaths in diabetic patients are due to coronary artery disease, 
cerebro-vascular accidents and peripheral vascular disease. 
Major risk factors which contribute towards cardiovascular diseases among diabetics 
are hypertension, dyslipidemia, hyperglycemia and obesity. There has been a direct 
correlation between cardio vascular complications and chronic hyperglycemia in various 
interventional studies
7,8
. The state of chronic hyperglycemia has been now measured by 
HbA1c, which averages the blood sugar levels of both fasting and post prandial states
9,10
. 
Diabetes affects both the vascular system and the myocardium of the heart. CAD is 
the most common cardiac manifestation in diabetic patients, followed by dilated 
cardiomyopathy and autonomic cardiovascular neuropathy. 
  Women who have diabetes loose their protection against coronary artery disease
11
. 
Cardio vascular disease accounted for 65% of death in women with diabetes in a western 
based population study
12
. 
In OASIS study
13
 it was found that diabetes increased the mortality risk by 57.6% and 
in the FINISH study it was observed that men with diabetes had 28day mortality risk of 
58%
14
. The relation between diabetes and CAD was further supported by the INTERHEART 
study
15 
Presenting high blood sugar levels has been considered as an independent risk factor 
of death in patients with or without diabetes
16
. High blood sugar levels at admission can 
either be diabetes or due to stress hyperglycemia or impaired glucose tolerance.
 
Hence it is important to study the spectrum of clinical presentation and the patterns of 
involvement of CAD in both diabetics and non-diabetics. It has been proved in many studies 
that diabetes increases the mortality risk in CAD.  
3 
 
The varying patterns of involvement of CAD in patients in relation to their glycemic 
status was studied in detail in a point to analyse any profound differences existed in the 
prediabetic group. The severity of coronary artery involvement in diabetics, prediabetics and 
non-diabetics were assessed quantitatively by means of GENSINI score
17
 [Angiographic 
severity score] in our study. We have analysed the changes in patterns of CAD in patients 
according to their glycaemic status. The quantitative comparison of CAD and its influence by 
blood sugar levels and glycaemic status has been analysed in this study. 
Prevalence of Diabetes in INDIA and its burden  
 As of in 2011 International Diabetes federation (IDF) stated that 61.3 million Indians 
were suffering from diabetes. They have speculated a further rise to 101.2 million by the year 
2030. The prevalence of diabetes in Indian studies is 7.3% vs 3.1% in urban and rural areas 
respectively
18
. In Indian reports, the prevalence of cardiovascular disease among diabetics is 
30.4 per cent
19
and 39.1 per cent
20
 in national and international prospective registries 
respectively. 
In India, CAD incidence is increasing over the last 30 years, while a declining trend 
has been noted in the western population
21
. Reports have shown that Asian Indians have 3-4 
times higher risk of CAD than white Americans, 20 times higher than Japanese and 6 times 
higher than chinese
22,23 
 The reported incidence of CAD among people less than 40 years of age is around 12-
16%. Of which 52% of CVD deaths occurred in people below 50 years, and 25% of acute 
myocardial infarction (AMI) occurred in people less than 40 years in INDIA
21
.
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AIM OF THE STUDY 
 
Primary Aim:  
 
1. To assess the severity of CAD by coronary angiography in pre-diabetic, diabetic and 
non-diabetic  patients presenting with acute coronary syndrome 
2. To assess the correlation between glycemic control and severity of CAD 
 
Secondary Aim: 
1. To assess the relationship between the duration of diabetes and severity of CAD in 
diabetic patients 
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REVIEW OF LITERATURE 
History of diabetes 
Egyptian physician Hesy-Ra first mentioned in the manuscripts of Ebers Papyrus in 
1500 BC mentioning it as ‘too great emptying of urine’24. In Indian medicine, Charak and 
Sushrutha, had written between 400 and 500 BC. Urine in diabetes was described by Charak 
as ‘madhumeha’ or honey urine noting that the urine would attract ants. They were also the 
first to separate Type 1 and Type 2 diabetes as separate conditions referring Type 2 diabetes 
to be more associated with overweight
25
. Greek physician Aretaeus of Cappodocia gave a 
brief description of diabetes, in 12O CE, which he mentions it as ‘the melting down of flesh 
and limbs into urine’.  
It was in 1889, Joseph Vonmering and Oskar minkowski were the first to discover an 
association between pancreas and diabetes. They experimented in dogs and found that after 
removing their pancreas, they developed symptoms and signs of diabetes after which they 
died shortly
26
. Paul Langerhans discovered the islets of Langerhans in 1869, which were the 
chief cells of regulating glucose metabolism in the body
27
.  
Banting, Best, and colleagues with chemist Collin with their experiments led to the 
invention of insulin preparation and their first usage in 1922
28
. 
In 1923, Nobel prize was awared to  Banting and Macleod in the field of Physiology 
Medicine. The United Nations announced November 14 as ‘The World Diabetes Day’ in 
honour of Frederick Banting’s birthday. 
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History of coronary artery disease 
William Heberdan an English physician in 1768 announced his observations about the 
relationship of coronary vascular anatomy and ischemic heart disease. For a long time in 
history even up to 19
th
 century the disease was called the ‘Heberdan’s disease’  
Ludwig Hekben in 1879, by his studies concluded that myocardial infarction was due 
to coronary obstruction secondary to thrombosis. 
In 1929, Werner Forssmann was the first to undergo self human catheterization, 
which he did on himself. Forssmann, a urologist while working on his experiments 
introduced a catheter into his jugular vein, and he immediately took an X-ray and found it to 
be inside the right atrium
29,30
.  
According to Cournand, the first catheterization was done by Claude Bernard in 1844 
in a horse
31
. André Cournand together with Dickinson Richards successfully repeated in 1941 
the trial of Forssmann. With their repeated attempts and experiments they were finally able to 
push the catheter in to right ventricle and take angiograms. Finally in 1950’s the forthcoming 
experiments by them were a milestone in history towards the present day cardiac  
interventions
32
. 
Coronary arteriography and ventriculography became the gold standard for studying 
the vessel anatomy and left ventricular pump function. They gave valuable information and 
made way for surgical treatment for coronary revascularizations. The initial attempts and 
repeated experiments by Dotter and Judkins, Andreas Gruntzig led to the advances in 
invasive cardiology.
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DIABETES AND CAD 
Diabetes mellitus is a chronic illness characterized by hyperglycemia resulting due to 
defects in insulin secretions, insulin actions or both. The chronic state of hyperglycemia 
results in both microvascular and macrovascular complications which causes damage to 
various organs, especially the eyes, kidneys, nerves, heart and blood vessels. 
Classification of Diabetes mellitus 
Classification of diabetes according to American diabetes association (2011)
33 
include four clinical classes: 
 
 
Type 1 diabetes  characterized by Beta cell destruction, resulting in absolute 
insulin deficiency 
Type 2 diabetes  Characterized by defects in the secretion of insulin and 
insulin resistance 
specific types genetic defects in β cell function, diseases of the exocrine 
pancreas (such as cystic fibrosis), genetic defects in insulin 
action, and drug or chemical-induced (such as in the 
treatment of HIV/AIDS or after organ transplantation) 
Gestational diabetes mellitus 
(GDM) 
 
diabetes during pregnancy 
8 
 
Criteria for the diagnosis of  diabetes
33 
HbA1C > 6.5%. 
or 
FBS>126 mg/dl . (Fasting is defined as no food / caloric intake for at least 8 h) 
or 
2 hr plasma sugar >200 mg/dl during an OGTT. 
or 
In a patient with random plasma glucose >200 mg/dl and classic symptoms of hyperglycemia 
or hyperglycemic crisis. 
Categories of increased risk for diabetes (prediabetes)
33 
FBS 100–125 mg/dl    ( IFG ) 
or 
2-h plasma glucose in the 75-g OGTT : 140–199 mg/dl (IGT) 
or 
HbA1C 5.7–6.4% 
Definition of Myocardial Infarction (ESC/ACCF/AHA/WHF Expert Consensus 
Document)
34 
Acute myocardial infarction is defined as evidence of myocardial necrosis in a clinical 
setting consistent with acute myocardial ischemia.  
9 
 
Any one of the following criteria meets the diagnosis for MI: 
Detection of a fall or rise in cardiac enzymes with at least one of the following:  
 Symptoms of myocardial ischemia. 
 New onset or presumed new significant ST-segment / T wave changes or new left 
bundle branch block (LBBB). 
 Development of pathological Q waves in the ECG. 
 Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality. 
 Identification of an intracoronary thrombus by angiography or autopsy. 
CORONARY ATHEROSCLEROSIS 
 The process of atherosclerosis starts with the process of adherence of circulating 
blood monocytes to the endothelium. These monocytes then migrate to the sub-endothelial 
space, and further gets activated into monocyte-derived macrophages. Low-density 
lipoprotein (LDL) particles circulating in plasma slowly invades into the endothelium and 
gets oxidised. The process of lipoprotein oxidisation has been observed since child hood. 
These oxidised lipoprotein particles releases cytokines which attracts the monocytes
35,36
. This 
initial insult to the endothelium triggers an inflammatory response. Monocytes enter the 
arterial wall from the bloodstream and the platelets get adhered to the area of inflammation. 
The monocytes differentiate into macrophages, which ingest the oxidized LDL, and turns into 
specialised cells called the "foam cells"
37,38
. These foam cells gradually evade and accelerate 
the inflammatory process. There is proliferation of smooth muscle cells. They slowly migrate 
from the tunica media into the tunica intima in response to cytokines. This causes the 
formation of a fibrous capsule covering the fatty streak. Enzymatic degradation occurs by 
10 
 
time and erodes the fibrous membrane beneath the endothelium. As time passes, the 
endothelial cap separating the plaque and blood flow becomes thin and fragile. The 
mechanical stress on the arteries causes these thin membrane to rupture and causes spilling of 
these plaque contents into blood stream triggering thrombosis
39
. Blood clotting system gets 
activated and forms a clot around this site of plaque rupture.  This results in unstable angina. 
Figure 1: Pathogenesis of atherosclerosis 
 
Figure 2: Plaque formation 
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Figure 3:  Evolution of Atherosclerosis 
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PREDIABETES 
Prediabetes (IFG and or IGT) is a stage in the natural history of diabetes. It represents 
a clinical state for (1) progression to diabetes mellitus (increased risk for diabetes) and (2) an 
increase in cardiovascular and possibly microvascular complications. 
The period of transition from prediabetes to diabetes is usually many years, but also 
can be rapid
40,41
.  Many studies and researches have estimated that upto 70% of individuals 
progress to diabetes
42
. The incidence is high in people with combined IFG and IGT rather 
than isolated IFG or IGT. People with IFG or IGT have 5-10% per year risk of developing 
diabetes, whereas people with normoglycemia have 0.7% per year risk of developing 
diabetes
42
.  
 Many studies have shown that prediabetes (IGT and IFG) is associated with an 
increased risk for cardiovascular problems
43,44,45
 .Usually they are associated with other 
cardiovascular risk factors, such as obesity particularly abdominal or visceral obesity, 
dyslipidemia and hypertension. There is increasing evidence that cardiovascular risk 
increases continually with increasing FBS levels. Prediabetes is associated with the 
development of microangiopathy. It was observed in 7.9% of patients with IGT to have 
diabetic retinopathy in Diabetes prevention program
46
. 
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Metabolic Syndrome and CVD 
Metabolic syndrome increases the risk of CAD. In Framingham study
48
, metabolic 
syndrome alone predicted ≈25% of all new-onset CVD.  Metabolic syndrome chiefly 
comprises of glucose intolerance, obesity, Hypertension, micro albuminuria, 
hyperinsulinemia with hypertriglyceridemia, low HDL levels, and hypofibrinolysis. The 
pathogenesis is mainly attributed to insulin resistance. Insulin resistance promotes the 
progression of atherosclerosis even before it develops into frank diabetes. Hence insulin 
resistance is considered as a independent risk factor for atherosclerosis.  
According to ATP III guidelines
47
 presence of any 3 of 5 risk factors listed below is 
considered as metabolic syndrome 
Risk Factor Defining Level 
Abdominal obesity, given as waist circumference  
    Men >102 cm (>40 in) 
    Women >88 cm (>35 in) 
Triglycerides ≥150 mg/dL 
HDL cholesterol  
    Men <40 mg/dL 
    Women <50 mg/dL 
Blood pressure ≥130/≥85 mm Hg 
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 At least three of the above ATP III criteria fit into metabolic syndrome. 
Atherosclerosis in type 2 diabetes mellitus is due to insulin resistance and hyperinsulinemia. 
Both of these mechanisms sets early in prediabetics, which precedes the onset of diabetes and 
impaired glucose tolerance by many years. 
 IFG is associated with hepatic insulin resistance, which results in fasting 
hyperglycemia, whereas IGT is predominantly associated with muscle insulin resistance. 
Most of the patients with prediabetes and metabolic syndrome are obese. There is an increase 
in adipose tissue which causes an increase in the levels of circulating free fatty acids (FFA) 
and adipokines
49
. These adipokines produce a proinflammatory and a prothrombotic state. 
The increase in FFA induces insulin resistance in muscles. In a chronic state they lead to 
lipotoxicity and produces beta cell dysfunction
50
. Elevated levels of FFA leads to increased 
hepatic glucose secretion and worsening hyperglycemia. They are also responsible for an 
increase in triglyceride levels and lowers HDL levels. Insulin resistance gradually presets a 
proinflammatory state and predisposes to cardiovascular disease
51
.  
Pathogenesis of CAD in Prediabetes
52
: 
The central process in the pathogenesis of prediabetes is the central obesity (measured 
by increased W:H ratio), which produces a state of insulin resistance and consequent 
hyperinsulinaemia. Because of the resistance to action of insulin there is a decreased cellular 
glucose uptake coupled with hepatic glucose production, which gets combined with β-cell 
exhaustion and produces a state of hyperglycemia. 
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Mechanisms: Hyper insulinaemia causes: 
1. Increased renal Na+/water re-absorption. 
2. Over activity of sympathetic nervous system. 
3. Increased Na+-H+ pump activity. 
4. Decreased Na+ -K+ ATPase activity. 
5. Increased Ca
2+
 concentration (calcium-cytosolic) in cells. 
6. Proliferation of arterial smooth muscle cells. 
 
Figure 4: Factors confounding in metabolic syndrome 
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Role of Insulin on Vascular Endothelium, in normal individuals: 
Insulin has both anti-atherogenic and atherogenic properties on vascular endothelium. 
Anti-atherogenic Atherogenic 
Insulin stimulates the production of nitric 
oxide  form vascular endothelium 
which causes 
 
Vasodilatation. Vascular cell growth 
Prevents platelet aggregation.  
Prevents growth of vascular smooth 
muscle cells (VSMC) 
Synthesis of extracellular Proteins and type 
IV collagen. 
Prevents migration and proliferation of 
VSMC. 
Modest effect on growth of VSMC and 
atherogenesis. 
Prevents formation of foam cells. Stimulation of growth factors. 
Inhibits expression of vascular 
adhesion molecules and intercellular 
adhesion molecules. 
Enhanced LDL receptor activity and 
cholesterol synthesis. 
  
Inhibits proinflammatory INF  
Inhibits production of monocytes 
chemo attraction protein-1 (MCP-1) 
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Mechanisms by which insulin produces Atherogenesis and anti-
atherogenesis: 
 
Insulin Resistance
53
: 
Insulin resistance is a metabolic state in which a normal concentration of insulin 
produces a less than normal biologic response. Insulin resistance results from abnormalities at 
any point in the sequence of insulin synthesis and secretion, to its transport and action on 
target tissue level i.e., at receptor, pre-receptor, post receptor levels. With respect to diabetes 
and CAD, both pre-receptor and post-receptor mechanisms are important. 
18 
 
Insulin resistance sets in hyperinsulinemia which has been implicated for an increased 
incidence of coronary artery disease
54-57
. Insulin causes vasodilation through secretion of 
endothelial nitric oxide synthase. These mechanisms are affected in insulin resistance. 
Endothelial dysfunction 
Endothelium has unique characteristics to maintain blood in a liquid state during 
circulation. These properties of endothelium are rendered by the expression of heparin 
sulphate and thrombomodulin on the surface of endothelium that inactivates the thrombin 
activation
58
. Endothelium also possesses fibrinolytic properties by production of urokinase 
type plasminogen activators, thus helps in maintaining an anti-thrombotic and anti-coagulant 
properties
59
. It also releases nitric oxide, prostaglandins, endothelin, angiotensin II. Nitric 
oxide produces vasodilation, which also reduces the inflammation caused by the adhesion of 
leucocytes and its migration thereby decreasing the smooth muscle cell proliferation
60-62
. All 
these protective mechanisms against atherogenesis are lost in Diabetes mellitus, increasing 
their relative cardiovascular risk. These changes are even apparent in patients with insulin 
resistance well before their progression into overt hyperglycemia. 
Hyperglycaemia 
In atherogenesis there is a migration of monocytes and T-lymphocytes into the intima, 
producing cytokines. These monocytes ingest the LDL and form the Foam cells, which are 
the early precursors of atherosclerosis
63,64
.  Hyperglycemia augments these pathological 
changes such as increased oxidative stress, non-enzymatic glycosylation of proteins and 
lipids, protein C activation and activation of transcription factors
65
. 
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Dyslipidemia 
In diabetes, hyperglycemia is associated with high triglyceride levels, increased 
atherogenic low density lipoproteins, and lower high density lipoproteins. Moreover 
hyperglycemia promotes the glycosylation of LDL, thereby promoting the inflammatory 
action of macrophages to form foam cells. All these factors contribute to an increased risk of 
atherosclerosis in diabetes
66
.  There is an increased hepatic free fatty acid concentration due 
to increased efflux from adipose tissues and insulin mediated skeletal muscle uptake, thereby 
liver increases VLDL production and cholesterol ester synthesis
67
. Overproduction plus 
decreased clearance of triglyceride rich lipoproteins due to the reduced action of lipoprotein 
lipase also leads to hypertriglyceridemia
68
. The increase in LDL particles are due to increased 
VLDL secretion and abnormal triglyceride and cholesterol transfer between VLDL and 
LDL
69,70
. 
Inflammation 
Diabetes is associated with up regulation of C-reactive protein, increased expression 
of VCAMs, Interleukins and activated protein C. All of which have been attributed to cause 
adverse cardiac outcomes
71-74
. Elevated C-reactive protein and VCAM levels are 
independently shown to be associated with poorer outcomes. 
Inflammation 
 
 ↑ IL-1β, IL-6, CD36, MCP-1 
 
 ↑ ICAMs, VCAMs, and selectins 
 
 ↑ Activity of protein kinase C 
 
 ↑ AGEs and AGE/RAGE interactions 
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Prothrombotic state and platelet function 
 There is an increased expressions of factor VII, Factor VIII, Von willebrand factor, 
plasminogen inhibitor in diabetic patients. There is also a profound alteration in the platelet 
function such as a) increased expression of glycoprotein IIb/IIIa, b) decreased Nitric oxide 
production c) decreased prostacyclin production and d) increased production of fibrinogen. 
All of which causes a procoagulant state in diabetic individuals
75
.  
 
Perturbations of platelet structure and function associated with diabetes
75 
 
 Reduced membrane fluidity 
 
 Altered Ca
2+
 and Mg
2+
 homeostasis 
 
 Increased arachidonic acid metabolism 
 
 Increased thromboxane A2 synthesis 
 
 Decreased nitric oxide and prostacyclin production 
 
 Decreased antioxidant levels 
 
 Increased expression of activation-dependent adhesion molecules  
                     (e.g., glycoprotein IIb/IIIa, P-selectin) 
 
 Increased platelet microparticle formation 
 
 Increased platelet turnover 
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Family history 
The familial trend in the occurrence of CAD and its genetic basis is found in many 
numbers of genes and are yet expanding in the field of research. Many studies including the 
‘Framingham study’ have found a significant association between family history and CAD 
and have now been considered as a separate independent risk factor for CAD
76-79
. Nearly 
more than 50% of patients who present with premature CAD are found to have genetically 
linked lipoprotein disorder
80
. The presence of additional risk factor such as smoking, 
sedentary lifestyle, obesity and dyslipidemia adds up to the relative risk of CAD in people 
with a positive family history of CAD. In a study in Finland, presence of family history of 
CAD was found to be associated with increased mortality risk. 
EFFECTS OF HYPERGLYCEMIA IN ACUTE MYOCARDIAL INFARCTION 
Patients with AMI with hyperglycemia, have increased risk of adverse outcomes in 
both diabetic and non-diabetic patients
80
. In acute MI, hyperglycemia was found to be 
associated with worse clinical outcomes. Presence of hyperglycemia resulted in higher 
incidences of congestive heart failure, cardiogenic shock and death in patients with ACS. A 
number of mechanisms have been entitled for this increased adverse outcomes in patients 
with hyperglycemia, of particular interests include 
1. Endothelial Dysfunction
81-88 
The possible accepted mechanism for hyperglycemia and poorer cardiovascular 
outcomes was the effect of acute hyperglycemia on the vascular endothelium. During 
situations of stress, the endothelium is subjected to various harmful effects such as 
dysfunction, dysregulation and failure. The resulting endothelial dysfunction ultimately leads 
22 
 
to altered angiogenesis, altered cell permeability, thrombosis and inflammation. Ultimately 
resulting in a loss of normal endothelial function. 
Increased endothelial adhesiveness and enhanced haemostasis are both thought to 
contribute to atheroma formation. Endothelial vasomotor dysfunction is another abnormality 
that precedes the development of overt atheromatous disease. Endothelial vasomotor 
dysfunction presumably reflects wider endothelial damage and it is a powerful predictor of 
atherogenesis and MI. 
2. Impaired collateral formation
89-91
 
Collateral development is a cardio protective mechanism in the normal vascular 
endothelium in response to myocardial ischaemia. The development of collateral vessels was 
found to be much more impaired in patients with diabetes. In hyperglycemia there is a 
significant rise in the levels of reactive oxygen species (ROS) in the arteriolar endothelium. 
This along with added endothelial dysfunction, decreased production of Nitric oxide synthase 
and reduced production of NO resulted in an impairment of vasodilation and permeability. 
Thus altering the formation of collaterals. This resulted in an impaired initial vasodilation and 
permeability, impairing the formation of collateral vessels. Thus impairing the initiation of 
arteriogenesis and causes a negative effect on the  remodelling of collateralization. 
3. Increased microvascular dysfunction after reperfusion (hyperglycemia and the No-
reflow phenomenon) 
92-98 
The no-reflow phenomenon is one of the major factors determining the prognostic and 
clinical outcome of MI. This has been observed in up to 30% of patients with ACS, even after 
a successful PCI. This results in a large area of myocardial necrosis, poorer recovery and 
more post MI related complications.  
23 
 
In a study by Iwakura et al, it was found that hyperglycemia was a major factor 
predicting the occurrence of no-reflow. The large infarcts caused more release of 
catecholamines, which alters the free fatty acid and glucose metabolism. Acute 
hyperglycemia also resulted in an increase in levels of P selectin, which further increases the 
plugging of leucocytes into the capillaries. This clumping or trapping of leucocytes in 
coronary capillaries and venules early after coronary reperfusion are much more frequently 
observed in the diabetic heart than in the non-diabetic heart. The plugging of leucocytes in 
the microcirculation might further add up to the no-reflow phenomenon. Acute 
hyperglycemia may also augment thrombus formation.  
4. Location of lesions 
Proximal segment and ostial segment lesions are more commonly observed in patients 
with Diabetes. These lesions are associated with a lower risk of procedural success and a 
higher rate of major adverse cardiac events even after PCI. Non-insulin dependent diabetes 
mellitus was observed to have more left main coronary artery disease
99
.
 
FACTORS ALTERING THE SEVERITY OF CAD IN DIABETES MELLITUS  
Sex 
In diabetes, women lose their cardio protection. Increased severity of disease in 
diabetic women has been noted in various studies
100-102
. Women with diabetes had 4 times 
more chance of developing cardiac failure (16% vs 3.8%) when compared to non-diabetic 
women. 
Possible mechanisms
103 
quoted for this increased mortality risk in female sex include  
a) Low HDL in diabetic women 
b) Insulin androgen interaction 
c) Poorer collateral circulation 
d) Diabetic cardiomyopathy has been noted more common in women  
24 
 
Duration of diabetes and severity of CAD 
Extent of coronary artery disease in terms of stenosis percentage has been studied in 
several studies with respect to duration of diabetes. Many studies have shown that the 
severity of CAD is increased in individuals with longer duration of diabetes
104-108
. The 
proposed mechanism being diabetic individuals are being exposed to the risk factors even 
before the establishment of clinical diabetes. 
 
Lipids 
Hypercholesterolaemia was considered as a risk factor in addition to CAD in a study 
of 204 patients in japan
109
. Lipoprotein(a) concentration and triglyceride rich lipoprotein 
particles were considered as confounding factors affecting the severity of CAD in patients 
with diabetes mellitus
110
. 
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 METHODOLOGY 
SOURCE OF DATA: 
This study was undertaken in PSG hospitals, affiliated to PSG institute of medical 
sciences and research, Coimbatore, Tamil Nadu during the study period between august 2011 
to December 2012. A total of 412 patients admitted with acute coronary syndrome in the 
study period who subsequently underwent coronary angiogram were included in the study. 
METHODOLOGY: 
All patients were evaluated in detail as per their symptomatology, a detailed physical 
examination, routine blood investigations with blood sugar estimation and HbA1c, ECG and 
ECHO were done at admission. They were categorized into non-diabetics, diabetics and pre-
diabetics according to their HbA1c levels. Diabetic patients were subcategorized according to 
their hbA1c levels (good control = <6.5, sub optimal control = 6.5-8.9, poor control = >9). 
Those patients in pre-diabetic range were evaluated with FBS, PPBS, subjected to oral GTT 
if necessary and subcategorized into impaired fasting glucose, impaired glucose tolerance or 
both. All patients were medically stabilised and subjected to coronary angiogram as an when 
it was indicated. The angiographic severity of the coronary artery disease was assessed using 
the Gensini score. Proper consent was obtained from individuals enrolled into the study. 
Ethical clearance was obtained as per institution norms. Statistical analysis was assessed 
using Mean ± standard deviation, Pearson’s correlation coefficient, Chi square test and 
ANOVA tests using SPSS software. 
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Inclusion Criteria: 
 Patients admitted with acute coronary syndrome  ( STEMI, NSTEMI , Marker 
positive unstable angina) who underwent invasive coronary angiogram were included 
in the study  
Exclusion Criteria: 
 Patients with known ischemic heart disease and proven CAD. 
 Patients with anaemia, renal failure or other known systemic illness. 
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PROTOCOL OF THE STUDY 
 
Acute coronary syndrome 
ENTRY POINT 
 
DIABETIC CAD                                                                                 NON-DIABETIC CAD 
• Known diabetic•                                                                                 Not a known diabetic  
 
HISTORY 
 Typical/ atypical presentation of CAD (chest pain, dyspnea, sweating, abdomian pain, 
syncope ) 
 Presence / absence of diabetes 
 Duration and control of diabetes 
 Risk factors (Smoking / Family history of IHD/ hypertension) 
 History of diabetic/ hypertensive complications 
 Other significant history 
 
CLINICAL EXAMINATION 
 Stigmata of hypercholesterolemia 
 Vital signs 
 Pulse (look for rhythm disturbance) 
 BP (look for hypertension/ hypotension) 
 Cardiac status by Killip classification 
 ECG (Type of CAD/ rhythm disturbance) 
 
PATIENT STABILIZATION 
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INVESTIGATIONS 
 Routine blood and urine 
 RBS, FBS & PPBS 
 HbA1c 
 Blood urea, S.creatinine, Urine –Microalbuminuria, Assess nephropathy (if present) 
 Lipid profile  
 Look for dyslipidemia and risk category 
 Fundus examination Diabetic/ hypertensive changes 
 Cardiac enzymes : Trop T 
 
ESTABLISH DIAGNOSIS 
Type of CAD: 
 STEMI AW / IW / IW + RV, NSTEMI, Unstable angina 
Echocardiography: 
 Regional wall motion abnormality 
 Systolic dysfunction 
 Diastolic dysfunction 
 
Angiography: 
 Gensini score – categorisation 
Observe Clinical Course 
 
Complications        No complications 
 LV dysfunction 
 Rhythm disturbances 
 Co-morbid conditions 
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DEFINITIONS: 
Coronary Artery Disease (A.M.I) is defined in the presence of minimum 2 of following
34
. 
1. Chest pain suggestive of Cardiac Origin. 
[Retrosternal squeezing. Radiating, increases with exertion, not relieved byrest and nitrates 
and associated with sweating.] 
2. Trop T positive. 
3. Electrocardiographic changes. 
 This consists of ≥ 1 of the following. 
a) ST segment elevation of more than 2mm from J Point in 2 related electric fields with 
typical evolutionary changes.  
b) Presence of new pathologic Q waves in 2 related electric fields. [for Q-M.I.] 
c) Non Q-M.I. with ST depression and T inversion  
 
DIABETES (ADA CRITERIA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Criteria for the diagnosis of  diabetes
33 
HbA1C > 6.5%. 
or 
FBS >126 mg/dl . ( Fasting is defined as no food/ caloric intake for at least 8 h ) 
or 
2-h plasma glucose >200 mg/dl  during an OGTT. 
or 
In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random 
plasma glucose >200 mg/dl. 
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Classification of Hypertension (JNC7) 
Blood Pressure 
classification 
SBP mmHg 
 
DBP 
mmHg 
Normal       <120 and <80 
Prehypertension 120–139 80–89 
Stage 1 140–159 90–99 
Stage 2 >160 >100 
 
Classification of Lipid profile 
Third Report of the National Cholesterol Education Program (NCEP) 
Total Cholesterol 
(mg/dL) 
LDL Cholesterol 
(mg/dL) 
Triglyceride 
(mg/dL) 
Serum HDL 
Cholesterol (mg/dL) 
<200 Desirable <100 Optimal <150  normal <40  Low HDL 
200–239 Borderline 
High 
100–129 Near optimal 150–199  borderline 
high 
>60  High HDL  
High 
>240 
above optimal 
130–159 
200–499  high  
 160–189 High >500  very high  
 >190 Very High   
Categories of increased risk for diabetes (prediabetes)
33 
FBS  100–125 mg/dl  ( IFG ) 
or 
2-h plasma glucose in the 75-g OGTT:  140–199 mg/dl  (IGT) 
or 
HbA1C 5.7–6.4% 
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Severity of CAD 
 
Gensini score was used to assess the severity of CAD
17
. 
Specific score is used to assess the narrowing of the coronary artery. First the percentage of 
stenosis is assessed. 
Stenosis score Percentage of occlusion 
1 1 – 25 
2 26 - 50 
4 51 - 75 
8 76 - 90 
16 91 - 99 
32 Complete occlusion 
 This stenosis score is then multiplied by a factor according to the importance of the 
coronary artery. The multiplication factor for a left main coronary artery (LMCA) lesion is 5, 
2.5 for proximal left anterior descending artery (LAD) and proximal circumflex artery (LCX) 
lesions, 1.5 for a mid-LAD lesion, and 1 each for distal LAD, mid LCX, distal CX and right 
coronary artery. The multiplication factor for any other branch is 0.5. 
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FLOW CHART OF THE STUDY 
 
History 
 
 
 
 
 
 
                                                                                                     
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Categorization 
with HbA1C 
IGT 
6.5-9 > 9  ≤6.4 
Coronary Angiogram: 
Severity – Gensini score 
0-20,    20-40,    40-60,    60-80,    80-100,    100-120,    120-140,  >140 
 
 
IFG 
Non Diabetics Pre Diabetics Newly detected 
Diabetes 
Diabetics 
Acute Coronary Syndrome 
History 
Excluded 
 Known CAD 
 Other Systemic 
Diseases 
H/o Diabetes No Previous 
 H/o Diabetes 
 
HbA1c 
Oral GTT 
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RESULTS AND OBSERVATION 
 There were 412 patients with first time ACS in the study population. Of them 213 
were Diabetics, 123 were non-diabetics, and 76 were prediabetics 
CATEGORISATION IN THE STUDY GROUP 
Table 1 Group distribution of study population 
Group Total number of cases Percentage (%) 
Diabetics 213 51.7 
Prediabetics 76 18.4 
Non diabetics 123 29.9 
Total 412 100 
 
 
SEX DISTRIBUTION AMONG STUDY GROUPS 
Table 2 Sex wise distribution of study group 
Group Male (%) Female (%) Male : Female 
Diabetics 174       (81.7) 39          (18.3) 4.46:1 
Pre-Diabetics 64         (84.2) 12          (9.8) 5.33:1 
Non-Diabetics 106       (86.2) 17          (13.8) 6.23:1 
 
There was male predominance in all the study groups, with the highest noted in non-diabetics 
with 6.23:1 
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Figure 5: Sex distribution 
 
 
AGE WISE DISTRIBUTION OF STUDY GROUPS 
Table 3 Mean age at presentation 
Group Mean Age 
Diabetics 56.3± 10.2 
Non diabetics 54.5 ±12.2 
Pre diabetics 54.4± 9.3 
 
Mean Age at presentation was higher in diabetics with 56.3 years. 
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Table 4 Age distribution of the study groups 
Age in 
years 
≤45 % 46-60 % 61-75 % ≥75 % Total 
Diabetics 34 16 102 47.8 71 33.4 6 2.8 213 
Pre-
Diabetics 
15 19.8 39 51.3 22 28.9 - - 76 
Non-
Diabetics 
28 22.8 51 41.5 38 30.9 6 4.8 123 
 
Figure 6: Age distribution of study groups 
 
In all the 3 groups, patients in age group between 46-60 years were mostly affected. 
There were no patients above 75 years in the prediabetic group. In patients above 61 years 
most of them were non-diabetics. 
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SYMPTOM ANALYSIS OF STUDY GROUPS  
Table 5: Symptom analysis of study groups 
Symptom Diabetics Pre diabetics Nondiabetics 
Number Percentage Number Percentage Number Percentage 
Chest pain 208 97.5 74 93.7 119 96.75 
dyspnea 33 15.5 13 17.1 20 16.3 
sweating 112 52.6 35 46 54 43.9 
Abdominal 
pain 
15 7 3 3.95 5 4.1 
Giddiness / 
syncope 
9 4.2 3 4 5 4.1 
 
 There were no notable differences in the presenting symptom among the study 
groups. Most common symptom being chest pain and sweating in all the 3 groups. 
 
Figure 7: Symptom analysis of study groups 
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ACS DISTRIBUTION 
Table 6: ACS distribution among study groups 
Group Unstable
angina 
NSTEMI STEMI total Distribution of STEMI cases 
AW IW IW+
RV 
LW 
Diabetics 23 
10.8% 
70 
32.9% 
120 
56.3% 
213 68 40 9 3 
Pre-
Diabetics 
5 
6.6% 
24 
31.6% 
47 
61.8% 
76 25 19 2 1 
Non-
Diabetics 
13 
10.6% 
25 
20.3% 
85 
69.1% 
123 59 21 4 1 
                                                                                                                         P value 0.059 
 
 Of the ACS distribution, majority of the patients in all the 3 groups presented with ST 
elevation myocardial infarction. STEMI presentation was particularly higher in Non-
diabetics, compared to other groups. Whereas NSTEMI and unstable angina were higher in 
diabetic group. However it failed to prove statistical significance. 
Figure 8: Distribution of ACS among the study groups 
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RISK FACTORS IN STUDY GROUPS 
Table 7: Prevalence of risk factors in study groups 
Risk factor Diabetics Pre-Diabetics Non-Diabetics 
Hypertension 106   (49.7%) 26     (34.2%) 41     (33.3%) 
Smoking 56     (26.3%) 17     (22.4%) 27     (21.9%) 
Obesity 95     (46.6%) 36     (47.4%) 42     (34.1%) 
        P value 0.002 
Obesity was more prevalent in pre diabetics, followed by diabetics. Hypertension was 
more prevalent in diabetics. There was no much variation in the prevalence of smoking in the 
study groups 
Figure 9: Risk factors among study groups 
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LIPID ABNORMALITIES IN THE STUDY GROUPS 
Table 8: Total cholesterol and Triglyceride Levels in Study groups 
 Total cholesterol HDL 
Desirable 
(%) 
Borderline 
High   (%) 
High 
(%) 
Low 
(%) 
Normal 
(%) 
High 
(%) 
Diabetics 150  (71) 40  (19) 21  (10) 148 (69) 59  (28) 6  (3) 
Prediabetics 54  (71) 14  (18) 8  (11) 55  (73) 20  (26) 1  (1) 
Non Diabetics 94  (76) 22  (18) 7  (6) 78  (63) 44  36) 1  (1) 
 
 There was no much observational variation in the levels of total cholesterol in the 
study groups. Whereas lower levels of HDL cholesterol was noted more in Prediabetics.  
Very high levels of LDL cholesterol was noted in 9% of prediabetics and 6% of Diabetics. 
 
Figure 10: Total cholesterol and Triglyceride Levels in Study groups 
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TRIGLYCERIDE AND LDL LEVELS  
Table 9: Triglyceride and LDL levels 
 Triglyceride LDL levels 
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Diabetics 128 
(60) 
55 
(26) 
28 
(13) 
2 (1) 54 
(26) 
74 
(34) 
43 
(20) 
29 
(14) 
13 
(6) 
Prediabetics 46 (61) 17 
(22) 
13 
(17) 
0 (0) 23 
(30) 
21 
(28) 
19 
(25) 
6 (8) 7 (9) 
Non 
Diabetics 
94 (76) 15 
(12) 
13 
(11) 
1 (1) 30 
(24) 
42 
(34) 
32 
(26) 
16 
(13) 
3 (3) 
 
 
Figure 11: Distribution of Triglyceride and LDL levels 
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ANGIOGRAPHIC SEVERITY OF CAD IN DIFFERENT GROUPS 
Table 10: Angiographic severity of CAD in different groups 
Group Mean HbA1c Mean Gensini score P value 
Diabetics 8.23±1.88 47.1±31.1  
0.049 PreDiabetics 6±0.19 41.5±25.1 
Non diabetics 5.40±0.30 38.45±33.9 
  
The severity of CAD was higher in Diabetics with a mean gensini score of 47.1, 
followed by Prediabetics with 41.5 and Non diabetics with comparatively lower involvement 
of severity of CAD with a mean gensini score of 38.5. (P value 0.049) 
 
Figure 12: Angiographic severity of CAD  in different groups 
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DISTRIBUTION OF GENSINI SCORE IN PREDIABETIC GROUP 
Table 11: Distribution of gensini score in prediabetic group 
Group Total patients 
(% among prediabetics) 
Mean gensini score 
IFG 57        (75) 44.4±25.3 
IGT 58        (76.3) 41.03±25.7 
IFG & IGT 43        (56.5) 43.86±26.85 
         P value 0.12 
 Around 56% of patients in prediabetic group had both IFG and IGT. There was no 
much statistically significant difference in severity of CAD among these groups. 
 
DURATION OF DIABETES AND GENSINI SCORE IN THE DIABETIC GROUP 
 The severity of CAD was higher in patients with diabetes for more than 5 years.  
There was statistically significant correlation between the duration of diabetes and severity of 
CAD in diabetics. 
Table 12: Duration of diabetes and gensini score in the diabetic group 
Duartion 
N
ew
ly
 
d
et
ec
te
d
 
0
-1
 y
rs
 
1
-3
y
rs
 
3
-5
 y
rs
 
5
-1
0
y
rs
 
>
1
0
y
rs
 
Diabetic 
group 
56 14 33 34 40 36 
Mean gensini 
score 
34.5 27.4 26.8 42.5 57.8 85 
 
Correlation coefficient r=0.69, p=<0.001 
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Figure 13: Duration of diabetes and gensini score in the diabetic group 
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Figure 14: Correlation between duration of diabetes and gensini score in diabetics 
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r = 0.69,  p= <0.001 
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ASSOCIATION BETWEEN GLYCEMIC CONTROL (HBA1C) AND GENSINI 
SCORE IN DIABETICS  
Table 13: Association between glycemic control (HbA1c) and gensini score in Diabetics 
Glycemic control hbA1c Total cases Mean gensini 
score 
P value 
Good   <6.5 14 53.2± 27.8  
0.484 Suboptimal 6.5-8.9 141 45.1 ±30.9 
Poor >9 58 50.4 ±31.6 
 
There was no statistically significant correlation with the glycemic control as assessed 
by HbA1c levels to the severity of CAD. 
Figure 15: Correlation between HbA1c and gensini score in diabetics 
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Figure 16: Correlation between HbA1c and gensini score in prediabetics 
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BLOOD SUGAR LEVELS AMONG THE GROUPS 
Table: 14 Blood sugar levels among the groups 
Group Mean Random 
blood sugar (mg/dl) 
Mean Fasting blood 
sugar (mg/dl) 
Mean post prandial 
blood sugar  (mg/dl) 
Diabetics 205±86.7 150.9±58.5 188.5±55.3 
Prediabetics 134.7±27.4 110.3± 13.38 148.9±16.6 
Non diabetics 120± 31.7 111.35±93.69 134.1±17.11 
 
 
CORRELATION COEFFICIENT BETWEEN SUGAR LEVELS AND GENSINI 
SCORE  
Table 15: Correlation coefficient between sugar levels and gensini score 
Group  Random blood 
sugar (mg/dl) 
 Fasting blood 
sugar (mg/dl) 
Post prandial blood sugar  
(mg/dl) 
Diabetics 0.0001 0.0079 0.0043 
Prediabetics 0.211 0.179 0.127 
Non diabetics 0.069 0.012 0.008 
 
The mean blood sugar levels at admissions were higher in the diabetic group. There 
was a direct positive correlation between blood sugar levels and the gensini score in all the 3 
groups. 
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CORONARY ARTERY INVOLVEMENT IN DIFFERENT GROUPS 
Table 16: Coronary artery involvement in different groups 
 Single 
vessel 
% Double 
vessel 
% Triple 
vessel 
% P value 
Diabetics 105 49.3 46 21.6 62 29.1  
<0.001 Prediabetics 51 67.1 14 18.4 11 14.5 
Non Diabetics 88 71.54 17 13.8 18 14.6 
 
 
Figure 17: Coronary artery involvement in different groups 
 
 Presence of Triple vessel disease was 29.1% in diabetics and 14.5% and 14.6% 
among prediabetics and non diabetics respectively. Single vessel disease was seen more in 
non-diabetics. Single vessel disease was found in 71.54% of non diabetics and 49.3% of 
diabetics. Triple vessel disease was more common in diabetics, whereas single vessel disease 
was more common in non-diabetic and pre-diabetics. These observations were statistically 
significant with a p value of <0.001. 
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DISCUSSION 
 
A total of 412 patients admitted with first time acute coronary syndrome during the 
study period were analysed. Of which 213 patients were diabetics and 123 were non-diabetics 
and 76 were pre-diabetics. Majority of the patients were diabetics. We compared the mean 
age, sex, risk profile, lipid abnormalities, clinical profile, type of ACS among each group. 
Correlation between glycemic status according to FBS, PPBS, HbA1c levels and severity of 
CAD assessed by gensini score were analysed. As with other studies diabetics were the 
majority in our study.  
AGE AND SEX DISTRIBUTION 
The mean age of presentation in diabetics was 56.3± 10.2 years, non-diabetics 54.5 
±12.2 years, and pre-diabetics 54.4± 9.3 years. There was no much difference in the mean 
age of presentation in the study groups. In all the 3 groups most of the patients were in the 
age range between 46 to 60 years.  In patients less than 45 years, non-diabetics were more 
affected than diabetics.  In the GUSTO-1
111
trial, it was observed that diabetic patients were 
older when compared to non diabetic patients, similar results were observed in our study.  
Males were more affected in all the three groups, with the highest noted in non-
diabetics with a sex ratio of 6.23:1 and lowest ratio in diabetics with 4.46:1. It is obvious that 
diabetic females had more prevalence of CAD when compared to pre-diabetics and non-
diabetics. Pre-menopausal females in general have protection against IHD, but this cardio 
protection is lost in the presence of diabetes. 
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SYMPTOM ANALYSIS 
Chest pain followed by sweating was the predominant symptom in all the 3 groups. 
Atypical symptoms such as abdominal pain, giddiness were higher in the diabetic group.  
In a study by soler et al
112
 diabetic patients had more atypical presentations of ACS 
with heart failure, vomiting, collapse, confusion or CVA, which led to increased risk for them 
going undiagnosed and increased mortality. 
PATTERN OF ACS IN STUDY POPULATION 
In all the 3 groups, ST elevation myocardial infarction was the most common type of 
ACS. STEMI was particularly higher in the non-diabetic (69.1%) and pre-diabetic group 
(61.9%). This may indirectly denote that prothrombotic mechanisms may be responsible for 
ACS among these groups. NSTEMI and unstable angina were higher in diabetic patients.  Of 
the STEMI distribution, anterior wall MI was the most common type followed by inferior 
wall myocardial infarction in all the three groups. 
RISK FACTORS: 
Of the risk factors studied, hypertension was more prevalent in the diabetic group. 
49.7% of diabetic patients had hypertension. There was no much difference in the prevalence 
of hypertension among pre-diabetics and non-diabetics.  Similar higher prevalence of 
hypertension among diabetics was noted in other studies (GUSTO-l, Rancho Bernardo, 
UKPDS, Gokhroo et al) 
111-114 
Prevalence of smoking was also high in the diabetic group.  Obesity was higher in 
both pre-diabetic and diabetic patients. Obesity was observed in 47.4% and 46.6% of pre-
diabetic and diabetic patients respectively
115
.   
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LIPID ABNORMALITIES 
In comparing the total cholesterol levels, 19% of diabetics and 18% of pre-diabetics 
and 18% of  non-diabetics were in the borderline high risk category. Higher levels of total 
cholesterol were observed in 10%, 11%, 6% of patients in diabetic, pre-diabetic and non-
diabetic groups respectively.  
In comparing the HDL levels, HDL levels were lower in 69% and 73% of diabetics 
and pre-diabetics respectively. Whereas, only 63% of patients in non-diabetic group had low 
HDL levels. 
Hypertriglyceridemia was noted to be higher in the pre-diabetic group (17%), whereas 
only 13% of diabetic patients and 11% of non-diabetic patients had high triglycerides (200-
499mg/dl). Very high levels i.e. levels more than 500mg/dl was noted in 2 diabetic patients 
(1%) and 1 non diabetic patient (1%).  
In comparing LDL levels, percentage of patients with higher levels (i.e. LDL 160-
189mg/dl) in diabetic, pre-diabetic, and non-diabetic groups were 14%, 8% & 13% 
respectively.  Very high levels (i.e. >190mg/dl) were observed in 9% of pre-diabetics, 
followed by 6% in diabetic group and 3% in non-diabetic group. A role for LDL in diabetic 
patients in promoting coronary heart disease in recent clinical trials, e.g., the Scandinavian 
Simvastatin survival Study (4S)
116,117
, the Cholesterol and recurrent Events (CARE) 
trial
118,119
, and the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID)
120
 
has been well established. All these trials have shown that aggressive LDL-lowering therapy 
reduces recurrent CHD events in patients with diabetes. 
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SEVERITY AMONG DIABETICS: 
Mean HbA1c levels in diabetics was 8.23±1.88, and 6±0.19 in pre-diabetic groups. 
We have used gensini score to estimate the severity of coronary artery disease. This gives a 
greater detail of assessment of CAD and does not ignore trivial lesions. Severity of CAD was 
higher in diabetics with a mean gensini score of 47.1±31.1, followed by pre-diabetics with a 
mean score of 41.5 ±25.1. Non diabetic patients had lesser severity of CAD with a mean 
score of 38.5±33.9. Our study is consistent with other studies, depicting higher severity of 
CAD in diabetics than in non diabetics. Results of other studies are shown in table  
Table 17: Similar studies comparing severity of CAD 
Principle investigator Number of cases in study Results 
Calton et al
121 
75 Higher score, more three 
vessel 
Natali et al
122 
2253 Higher score, greater effect 
on female patients 
Hamby et al
123 
100 Higher score, more three 
vessel 
Pajunen et al
124 
57 IDDM patients More severe extensive and 
distaldisease 
Thomas et al 
125 
59 More severe disease 
Abadie et al
126 
36 No difference 
Krishnaswami S et al
127 
516 More severe disease and 
more multivessel disease 
Mahdi moosavi et al
128 
50 More severe disease and 
more multivessel disease 
Peppes et al
129 
115 More severe disease 
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SEVERITY BY NUMBER OF VESSELS 
Multi vessel involvement was more in diabetics. 29.1% of diabetics had triple vessel 
disease, whereas only around 14% of pre-diabetic and non-diabetic patients had triple vessel 
disease. 71.5% of non-diabetic patients and 67.1% of pre-diabetic patients had single vessel 
disease, whereas only 49.3% of diabetics presented with single vessel disease. Pre-diabetics 
also had a trend towards single vessel disease. There are a number of studies showing higher 
involvement of multi vessel disease in Diabetes
123,127,128
. Similar results have been found in 
other studies using gensini score
121-123
. 
SEVERITY AMONG PREDIABETICS 
In our study we have quantitatively assessed the severity of CAD by using gensini 
score. There are hardly any studies available in pre-diabetics to postulate the extent of 
severity of CAD. Our study did not show any significant difference in the severity of CAD 
among pre-diabetics and non-diabetics. It has been well studied and proved that diabetic 
patients have more severe CAD. But no such major studies are available with pre-diabetic 
patients to show a higher severity of CAD. Of the pre-diabetic group in our study, 57 cases 
(75%) had impaired fasting glucose, 58 cases (76.3%) had impaired glucose tolerance and 43 
cases (56.5%) had both impaired fasting glucose and impaired glucose tolerance. There was 
no statistically significant difference in severity of CAD among these groups. Comparatively 
patients with isolated IFG had a higher gensini score. However patients with IFG, IGT and 
combined IFG & IGT had higher scores compared to non-diabetics. Yan et al
130
 showed 
higher severity of CAD in pre-diabetics compared to diabetics, However in his study patients 
with combined IFG & IGT had more severe disease compared to isolated IFG & IGT. 
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Pre-diabetic patients are at increased risk of death due to CAD
131
. This is chiefly 
attributed to the fact that most of the ACS in pre-diabetic patients was due to thrombus 
formation at sites of a vulnerable plaque. The first abnormality noted in patients with insulin 
resistance is IFG (or impaired glucose tolerance). The presence of IFG usually accompanies 
long-standing insulin resistance. Many prospective studies
132,133
 show that IFG or IGT is a 
risk factor for CVD, the degree of independence as a risk factor, however, is uncertain. 
DURATION OF DIABETES 
Of the 213 diabetic patients, 56 patients were newly diagnosed to have diabetes.  The 
mean duration of diabetes was 53 months in the diabetic group. It was observed that the 
severity of CAD was higher in patients who had longer duration of diabetes. Patients with 
long standing diabetes (i.e >10 years) had more severe CAD with a mean score of 85. There 
was a positive linear correlation between the duration of diabetes and severity of CAD. This 
was statistically significant. [Correlation coefficient r = 0.69, p= <0.001]. Studies by Tahir et 
al
134 
& Syvanne et al
35 
also found a positive linear correlation with duration of diabetes and 
severity of CAD. 
GLYCEMIC CONTROL  
Diabetics with good glycemic control (i.e. HbA1c level<6.5) had a mean gensini 
score of 53.2±27.8. Patients with suboptimal control (hbA1c 6.5-8.9) and poor control 
(HbA1c>9) had a mean gensini score of 45.1±30.9 and 50.4±31.6 respectively. But this was 
statistically insignificant. When comparing the association between HbA1c levels to the 
severity of CAD in diabetic patients, there was no statistically significant correlation between 
them. But among pre-diabetics there was a positive linear correlation identified between the 
HbA1c levels and gensini score [correlation coefficient r=0.129, p=<0.01]. Tahir
134
 and 
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Ayhan et al
136
 had found positive linear correlation between hbA1c levels and severity of 
CAD in diabetes patients, our study did not show any relation between them. 
The mean blood glucose levels at admission were higher in the diabetic group with 
205±86.7mg/dl.  Similarly mean fasting blood sugar levels were also higher in the diabetic 
group. 21 non diabetic patients had blood sugar levels >140mg/dl at admission, which could 
be due to stress hyperglycemia. There was a significant positive linear correlation between 
FBS, PPBS, presenting RBS and gensini score in all the 3 study groups. This implies that 
hyperglycemia is directly associated with more severe CAD.  
 
LIMITATIONS OF STUDY 
1. Number of patients in the study is small. Hence more studies on pre-diabetics and 
non-diabetics are needed in future 
2. Duration of study is short, Hence follow up of patients was not included in the study 
3. Possible underlying mechanism (such as insulin resistance, pro-thrombotic work up) 
in Pre-diabetic patients was not studied. Large prospective studies in pre-diabetic 
patients are needed in future for better understanding and planning management 
strategies.  
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CONCLUSION 
 
1. A total of 412 patients were studied, of which majority of the patients were diabetics 
(51.7%) 
2. Male predominance was noted in all the study groups 
3. Mean Age of presentation was 56.3± 10.2 among diabetics, 54.5 ±12.2 among non-
diabetics and 54.4± 9.3 among pre-diabetics. There was no much difference in mean 
age of presentation among study groups. Patients with age range between 46-60 years 
were commonly affected in all the study groups. 
4. Chest pain and sweating were the common presenting symptom in all groups 
5. STEMI was comparatively higher in non-diabetics. However this was statistically 
insignificant. 
6. Hypertension was more among diabetics, whereas obesity was higher in both Pre-
diabetics and diabetics. 
7. Diabetics had more prevalence of Low HDL. 9% and 6 % of Pre-diabetics and 
diabetics had very high LDL levels respectively. 
8. Diabetics had more severe CAD with a gensini score of 47.1 ±31.1, followed by Pre-
diabetics with a gensini score of 41.5±25.1. Non-Diabetics had comparatively less 
severe CAD with a gensini score of 38.45±33.9. 
9. Single vessel disease was more in pre-diabetics and non-diabetics. Whereas diabetics 
had more triple vessel disease. 
10. There was no significant difference in the severity of CAD among Pre-diabetic 
patients with IFG alone, IGT alone and combined IFG and IGT. 
11. Patients with diabetes had a significant positive linear correlation between duration of 
diabetes and severity of CAD. 
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12. There was no statistically significant correlation between HbA1c levels and severity 
of CAD in diabetics. 
13. Presenting blood sugar levels was found to have significant positive linear correlation 
with severity of CAD in all the three groups. This finding was more consistent in pre-
diabetic patients. 
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 ANNEXURE I 
LIST OF ABBREVATIONS USED 
CAD : Coronary Artery Disease 
DM : Diabetes Mellitus 
NIDDM : Non Insulin Dependent Diabetes Mellitus 
NCEP : National Cholesterol Education Program 
ATP : Adult treatment panel 
VLDL : Very Low Density Lipoprotein 
LDL : Low Density Lipoprotein 
HDL : High Density Lipoprotein 
HT : Hypertension 
HbA1C 
CVD 
ACS                              
ADA 
GDM 
FBS 
PPBS 
OGTT 
RBS 
MI 
cTn 
: Glycosylated Haemoglobin 
: Cardiovascular disease 
: Acute coronary Syndrome 
: American diabetes association 
: Gestational diabetes mellitus 
: Fasting blood sugar 
: Post prandial blood sugar 
: Oral glucose tolerance test 
: Random blood sugar 
: Myocardial infarction 
: Cardiac Troponin 
 URL 
LBBB 
PCI 
ECG 
CABG 
IFG 
IGT 
FFA 
VSMC 
CHD 
NO 
STEMI 
NSTEMI 
IHD 
CVA 
VCAM 
PAI 
: Upper reference limit 
: Left bundle branch block 
: Percutaneous coronary intervention 
: Electro cardiogram 
: Coronary artery bypass graft 
: Impaired  fasting glucose  
: Impaired glucose tolerance 
: Free fatty acid 
: Vascular smooth muscle cell 
: Coronary heart disease 
: Nitric oxide 
: ST elevation myocardial infarction 
: Non ST elevation myocardial infarction 
: Ischemic heart disease 
: Cerebro-vascular accident 
: Vascular cell adhesion molecule 
: Plasminogen activator inhibitor 
 
 
 
 
 
 ANNEXURE II 
Case Proforma:           
Name :    Age :     sex: 
Op.no:   IP.no:   unit: 
D.O.A:    D.O.D:    
Duration of stay: 
Diagnosis:  AW    IW   LW                                STEMI / NSTEMI 
WP:    Killip :       
HISTORY 
Typical/ atypical presentation of CAD: chest pain, dyspnea, sweating, abdomian pain, 
syncope ) 
DM : Yes / No                    Duration : …….. yrs     0-3 , 4-7, 7-10, >10 Newly detected 
Treatment details :  Not on treatment  /   Diet  /  OHA  /  OHA + insulin /  Insulin 
Risk factors :  smoking  (     yrs ) / family history / tobacco chewing /  DLP /        HT   ………yrs 
History of Diabetic  / hypertensive complications :  
Other significant history 
Clinical Examination 
PR :                   BP :              RR :         
Ht:                                                Wt                                        BMI                            WH ratio          
CVS – Features of LV dysfunction   :     present   /   absent 
ECG :       STEMI      AW   IW     LW   PW                                      NSTEMI 
ECHO :  RWMA : LAD / LCX /  RCA  / Global                         LV EF :  <30   /  30- 40  /  40-50  /  
>50 
Investigations : 
Hb  Ur  Cr  K+  Trop T 
FBS    PPBS   HbA1c :    < 5.7    5.7-6.4  6.5-7.5   > 7.5 
Oral GTT :   o hr =   120 mins :      
 Chol: 
TGl: 
HDL: 
LDL:  
 
Angiography :          LMCA / LAD /  LCX / RI / RCA /                   SVD  /  2VD /  TVD  /  LMCA 
 
 
Gensini score:  
 
0-20  20-40  40-60  60-80  80-100  100-120 
120-140 140-160  >160 
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amala doss i12016441 60 0 1 0 0 0 0 0 0 0 1 0 1 1 1 188 132 199 7.1 87 98 28 53 63 1 10
ammasaikal i12018664 68 0 1 1 1 0 0 0 1 0 0 0 0 1 1 1 568 274 302 7.56 226 59 52 112 47 3 30
andal i12022086 58 0 1 1 1 0 0 1 0 0 0 0 1 5 1 24 265 155 175 14.36 223 190 75 124 48 1 6
angathal i12015950 66 0 1 1 1 0 0 1 0 0 0 0 1 2 1 32 188 117 168 7.6 144 224 29 86 80 2 28
annamal i12007347 61 0 1 1 0 0 0 0 0 0 0 1 1 3 1 32 127 89 136 6.8 145 158 35 190 40 2 66
bagyam i12018138 65 0 1 1 0 0 0 0 0 0 0 1 1 1 1 66 265 187 207 12.17 163 85 31 115 70 2 44
ebinezar i12001408 55 0 1 0 0 0 0 0 0 0 1 0 1 1 12 158 111 175 7.08 122 105 21 77 60 1 4
geetha i11023860 41 0 1 0 0 0 0 0 0 0 1 1 2 1 62 195 126 174 12.5 242 141 32 176 58 1 14
gowri i11026940 61 0 1 1 0 0 0 0 0 0 1 0 1 5 1 1 1 175 121 165 9.5 156 105 35 98 56 2 38
gowri i12010496 65 0 1 1 0 0 0 0 0 0 0 1 1 5 1 4 190 114 184 6.8 210 110 40 156 69 2 25
indirani i12007297 61 0 1 1 1 1 0 0 0 0 0 1 2 1 6 182 111 185 7.2 180 101 43 129 66 3 36
jannama i12029042 46 0 1 1 1 1 0 1 0 0 0 0 0 1 5 1 63 158 168 169 6.59 235 81 56 167 40 1 30
jeenath begam i12021827 56 0 1 0 0 0 0 0 0 0 1 0 1 66 208 102 144 6.2 188 147 35 148 57 3 36
jothimani i12010572 51 0 1 1 0 1 0 0 0 0 1 120 258 101 243 10.2 164 157 38 101 61 1 90
kadeeja beebe i12016249 54 0 1 0 0 0 1 0 1 1 2 1 63 174 123 220 6.57 200 182 43 144 70 3 32
kanaka i11021550 70 0 1 1 1 0 0 1 0 0 1 1 3 1 42 165 153 166 7.86 147 116 28 107 52 1 32
kanmalam i12027136 68 0 1 0 0 0 0 0 0 0 1 41 148 92 133 7.9 216 199 36 158 60 3 14
mary loudi i11027692 58 0 1 1 1 p 0 1 0 0 1 5 1 40 130 144 158 6.33 192 183 38 118 60 1 38
natchaammal i12017952 58 0 1 1 1 0 0 0 0 0 1 1 4 1 124 188 88 122 11.86 232 116 48 163 38 3 75
palaniammal i11032642 67 0 1 0 0 0 0 0 0 1 1 5 1 36 302 204 252 10.7 203 147 67 115 80 1 24
palaniammal i11034868 61 0 1 1 1 0 0 1 0 0 0 1 75 306 199 185 9.37 155 174 22 101 60 1 88
radha chandran i12001946 53 0 1 1 1 1 1 0 0 1 0 0 0 1 5 1 60 412 196 265 11.9 157 58 43 102 60 1 4
ramathal i12013886 66 0 1 1 0 1 0 0 0 0 0 1 1 1 113 114 165 6.39 240 167 43 184 50 1 28
rathinam i12030491 60 0 1 1 1 0 0 1 0 0 0 1 7 1 68 341 142 165 7.1 148 83 37 94 66 1 35
ruckmani i12002013 58 0 1 0 0 0 0 0 0 1 1 6 1 45 117 100 120 8 145 90 40 155 70 1 22
sarasu i12018912 61 0 1 1 0 0 0 0 0 0 1 1 5 1 68 264 136 165 7.86 250 134 41 201 77 2 42
saroja i11034476 46 0 1 0 0 1 0 0 0 1 1 4 1 38 414 236 265 13.1 121 176 21 67 80 2 32
sarojini i11022708 61 0 1 1 1 0 0 1 0 0 0 1 3 1 64 291 125 165 10.6 148 191 27 92 69 1 34
seetha i12030657 37 0 1 1 0 0 0 0 0 0 1 1 5 1 68 206 175 185 6.9 134 166 35 78 44 3 68
selvi i12016052 46 0 1 1 0 1 0 0 0 0 0 1 36 117 99 122 6.57 158 68 48 99 48 2 48
senbaveni i12002907 56 0 1 0 0 0 0 0 0 1 0 1 34 401 320 202 14.5 298 197 43 221 65 3 22
subaitha i12007181 51 0 1 0 0 0 0 0 0 1 1 10 1 0 124 152 128 184 7.02 184 82 42 135 65 3 120
subbathal i11035580 66 0 1 1 1 0 0 1 0 0 0 1 10 1 132 300 148 199 12.2 237 181 37 167 63 3 74
suseela i11024395 59 0 1 1 1 1 1 0 1 0 0 0 1 4 1 75 112 96 152 8.2 101 79 20 68 50 1 68
usha i12002546 54 0 1 1 0 0 0 0 0 1 0 1 6 1 28 192 89 165 6.7 175 85 28 174 40 2 22
valliammal i12022737 63 0 1 1 1 1 1 0 0 0 0 0 1 128 309 297 165 11.5 244 115 46 189 53 1 80
vasantha mani i11024051 52 0 1 1 1 1 0 0 0 0 0 1 100 233 154 255 11.3 131 67 37 79 56 1 88
vasanthamani i12002492 66 0 1 1 1 0 1 0 0 0 0 1 5 1 120 322 225 275 10.21 123 120 24 76 56 3 60
vijayalakshmi i12004483 61 0 1 1 0 0 0 0 0 0 1 1 1 1 145 192 166 225 7 178 102 40 110 45 3 106
abdul i12003616 61 1 1 1 0 0 1 0 0 0 0 1 2 1 1 14 225 155 188 9 142 103 31 84 57 1 16
amalarajan i12027081 42 1 1 1 1 0 1 0 0 0 0 0 0 1 1 1 124 197 122 158 6.5 285 159 37 148 52 1 80
anbalagan i12011591 52 1 1 0 0 0 0 0 0 0 1 1 1 1 1 1 175 102 185 7 243 296 47 196 69 2 28
anbuselvan i12029050 47 1 1 1 1 1 1 0 0 0 0 0 1 3 1 1 1 169 213 285 8.8 254 131 22 208 52 1 28
angamuthu i12017662 64 1 1 0 0 0 0 0 0 1 0 0 1 34 166 94 165 6.9 203 152 42 185 40 2 48
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anthony i12016411 41 1 1 1 1 1 0 0 0 0 0 1 4 1 88 124 90 155 6.92 152 153 25 143 57 1 80
aravind shanmugam i12009403 48 1 1 1 1 1 0 0 1 0 0 0 1 2 1 1 36 398 372 399 9.5 251 297 42 163 59 1 12
arjunan i12025606 41 1 1 0 0 0 0 0 0 0 1 0 1 1 1 126 90 125 7 230 186 59 142 62 2 80
arumugam i11021280 43 1 1 1 1 1 0 0 1 0 0 0 0 1 2 1 62 235 158 175 8.85 156 142 27 128 53 3 55
arumugam i11023098 60 1 1 1 0 0 0 0 0 0 1 0 0 1 64 358 193 266 9.5 150 175 23 104 65 1 15
arumugam i11025132 59 1 1 1 1 1 1 0 0 0 0 0 0 1 1 1 224 109 188 6.4 190 180 34 94 56 3 122
arumugam i11032892 64 1 1 1 1 0 0 0 0 0 1 0 1 0 1 1 28 113 99 132 6.53 114 115 22 76 81 3 16
ayyavu i11030361 49 1 1 1 0 0 0 0 0 0 0 1 1 2 1 24 213 144 177 10.21 179 288 30 111 49 1 22
aziz mulik i11025803 65 1 1 1 1 0 1 0 0 0 0 0 1 1 1 188 90 155 6.42 193 153 27 140 80 2 32
babuji i12021586 46 1 1 1 0 1 0 0 0 0 0 1 1 1 1 62 224 128 164 8.95 168 222 43 156 59 2 36
balasubramaniam i11028349 65 1 1 1 0 0 0 0 0 0 1 0 0 1 72 297 135 169 12.08 155 86 37 92 58 3 48
balasubramaniam i12022051 60 1 1 1 1 0 1 0 0 0 0 1 20 178 99 154 8.2 208 167 61 126 68 1 24
boopathi i12025313 47 1 1 1 1 1 0 1 0 0 0 0 1 2 1 1 100 201 201 268 9.1 222 476 36 126 60 3 75
chinnappan i12031013 71 1 1 1 1 1 0 0 1 0 0 0 1 3 1 1 1 1 336 265 304 6.9 183 83 54 112 58 1 32
chinnaraj i11035062 48 1 1 1 0 0 0 0 0 0 0 1 0 1 62 120 120 186 7.4 126 149 27 76 50 1 42
chinnasamy i11034277 56 1 1 1 1 0 1 0 0 0 0 0 0 1 1 1 225 109 169 6.6 176 85 40 111 69 3 58
chinnasamy i12015739 71 1 1 1 0 0 0 0 0 0 0 1 0 1 1 13 114 95 145 7 110 125 29 65 56 1 24
deivasigamani i12016221 62 1 1 1 1 1 0 0 0 0 0 0 1 1 1 143 87 136 6.8 206 144 39 154 79 1 8
deventhiran i12026953 50 1 1 1 1 1 0 1 0 0 0 0 0 0 1 38 236 156 186 9.26 146 139 25 100 45 1 30
dharmalingam i12001428 78 1 1 0 0 0 0 0 0 0 1 1 5 1 1 0 62 234 244 275 8.11 107 78 37 57 62 1 14
dhayanan i12011391 36 1 1 1 1 0 0 0 0 0 0 1 35 72 111 146 7.2 126 145 35 165 66 1 25
dominic i12018582 48 1 1 0 0 0 0 0 0 0 1 1 5 1 60 258 102 169 6.9 120 85 45 103 55 2 18
duraisamy i12027178 60 1 1 1 0 1 0 0 0 0 0 1 4 1 1 1 151 133 168 6.2 161 190 28 113 48 1 18
elango i12013331 45 1 1 1 0 0 0 0 0 0 0 1 1 2 1 1 100 188 188 254 10.1 188 235 113 187 55 3 90
eswaran i11034646 37 1 1 1 1 p 0 0 1 0 0 0 0 1 1 1 313 111 176 11.4 171 143 32 109 44 1 75
ganesan i12027570 61 1 1 1 0 0 0 0 0 0 1 0 0 1 62 194 136 255 6.75 190 107 31 146 50 1 50
gopalakrishnan i12022243 73 1 1 1 1 0 0 0 0 0 0 0 1 1 3 1 0 110 133 114 165 8 218 54 64 157 30 3 75
gopalakrishnan i12027628 55 1 1 0 0 0 0 0 0 0 1 0 1 18 188 84 154 8.9 146 121 31 93 45 1 30
govindaraj i12011882 65 1 1 1 1 1 1 0 0 0 0 0 0 1 1 28 91 90 132 6.6 175 145 38 125 45 1 36
gunasekaran i11034203 39 1 1 1 1 1 0 0 0 0 0 0 1 110 249 135 246 7.87 264 209 37 190 65 3 112
jagajothi i12000417 66 1 1 1 1 0 0 0 0 0 0 0 1 1 3 1 65 248 156 232 8.96 200 200 33 130 75 3 30
jayaraj i12002664 52 1 1 1 1 1 1 0 0 0 0 0 0 1 1 60 338 161 224 9.2 230 179 32 169 45 1 18
jayaraj i12012434 62 1 1 1 0 0 0 0 0 0 0 1 0 1 1 1 106 139 220 7 180 144 36 129 48 3 68
john i12002729 63 1 1 1 0 0 1 0 0 0 1 1 1 1 189 129 180 7.08 213 86 39 158 58 3 44
kadhirullah i11023460 62 1 1 1 1 0 0 0 1 0 1 1 10 1 62 332 236 299 10.5 344 367 28 249 57 3 50
kalavendhan i12013713 46 1 1 0 0 0 0 0 1 1 5 1 120 108 188 222 8.29 281 243 35 204 45 2 18
kaliappan i12031942 65 1 1 1 0 0 0 0 0 0 0 1 1 136 198 171 190 7.25 120 127 25 78 28 3 102
kalisamy i12016939 59 1 1 0 0 0 0 0 1 0 1 1 1 1 175 114 166 9.9 189 126 37 136 50 1 30
kamnnaiyan i12003556 68 1 1 1 0 0 0 0 1 0 1 2 1 26 158 112 136 7 152 142 25 85 60 1 6
kandasamy i12001193 49 1 1 1 0 0 1 0 0 0 0 1 24 248 202 266 6.7 138 80 24 125 63 3 28
kannan i12018589 42 1 1 1 0 0 0 0 0 1 1 2 1 0 92 106 98 155 7.6 141 124 42 105 50 2 85
karuppusamy i12010492 61 1 1 1 1 1 1 0 0 0 1 2 1 1 25 91 107 123 6.9 163 125 21 125 68 3 28
karupusamy i12005782 44 1 1 1 1 1 1 0 0 0 1 5 1 1 1 1 110 103 133 6.6 174 434 25 95 77 1 4
kathirvel i12029919 60 1 1 1 0 1 0 0 0 0 1 60 168 111 147 6.68 148 84 28 102 50 1 28
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krishnamooorhy i12015757 61 1 1 1 1 0 1 0 0 0 1 5 1 109 332 290 336 10.1 173 146 42 119 41 1 80
krishnamoorthy i11025817 62 1 1 0 0 0 0 0 1 0 1 120 104 123 169 6.63 102 101 22 63 60 3 152
krishnan i12002554 44 1 1 1 0 0 0 0 1 0 0 1 1 1 1 122 101 144 7.11 142 114 33 83 64 1 34
krishnasamy i12003524 60 1 1 1 0 0 1 0 0 0 1 118 235 216 190 9.39 197 137 25 136 35 3 106
kumar i12008825 53 1 1 1 1 1 1 0 0 0 0 1 68 299 255 366 7.2 199 204 38 130 46 2 60
kunikam i12021173 56 1 1 1 0 0 0 0 1 0 1 5 1 34 170 105 155 7.6 165 148 36 148 65 1 15
laksmanan i11029760 59 1 1 1 1 0 0 0 0 1 0 1 3 1 122 171 128 165 6.42 199 181 31 124 22 3 68
mahalingam i11028142 56 1 1 1 1 1 0 1 0 0 0 1 1 66 103 116 136 6.88 123 118 23 74 62 3 38
mahendran i12014526 55 1 1 1 0 0 0 0 0 1 1 3 1 1 1 260 222 268 7.25 124 195 25 70 65 1 18
mandharchalam i12023522 83 1 1 1 1 0 0 1 0 0 1 6 1 1 30 199 177 188 6.32 126 53 36 83 62 3 30
mani i12023907 65 1 1 0 0 0 0 0 1 0 1 1 1 1 136 126 166 8.23 152 262 38 81 56 1 32
manikandan i12004615 46 1 1 0 0 0 0 1 0 0 1 28 212 193 327 9.3 190 125 35 133 52 2 34
manoharan i12028027 56 1 1 1 1 1 1 0 1 0 0 1 5 1 34 159 144 165 8 185 142 40 123 50 3 38
manokaran i11029958 45 1 1 1 1 p 1 0 0 0 0 1 1 1 1 201 188 236 7.2 259 175 32 178 60 1 26
michael raj i12018578 45 1 1 1 0 0 0 0 0 1 0 1 1 1 209 188 196 6.6 175 186 42 168 56 2 14
mohamad ali i12007101 66 1 1 1 0 0 0 0 0 1 0 1 68 131 129 114 7.04 133 89 29 93 60 3 36
mohammed i12024213 59 1 1 1 0 0 0 0 1 0 1 8 1 124 103 111 135 7.3 236 244 48 189 73 3 110
mohammed ali i12006918 51 1 1 1 1 1 0 0 0 0 1 14 90 86 124 7.6 174 111 28 119 65 2 27
murugaiyan i12009440 72 1 1 1 1 0 1 0 0 0 1 2 1 122 472 356 224 12 205 139 42 144 30 3 66
murugesan i12014293 60 1 1 1 1 0 1 0 0 0 1 2 1 1 1 1 321 222 185 9.54 196 142 39 142 57 3 75
murugesan i12024842 47 1 1 1 1 1 1 0 0 0 1 3 1 28 222 118 148 6.7 140 184 31 86 57 1 30
murugesh i11030815 53 1 1 1 0 0 0 0 1 0 0 1 1 1 235 201 285 7.8 185 136 57 105 55 2 55
muthusamy i11035932 76 1 1 1 0 0 0 0 0 1 1 5 1 130 238 255 322 7.48 267 149 30 192 64 3 152
muthusamy i12003150 76 1 1 1 0 1 0 0 0 0 1 1 1 1 160 106 148 7.2 127 119 20 82 52 2 38
muthusamy i12011096 64 1 1 1 1 1 0 0 0 1 5 1 34 199 129 185 6.9 169 161 35 112 66 1 30
muthusamy i12024239 48 1 1 1 0 0 0 0 1 0 1 1 1 1 120 269 221 265 10.9 199 305 45 116 65 3 65
muthusamy gounder i12012119 75 1 1 0 0 0 0 0 0 0 1 38 134 146 145 7.9 146 139 29 101 56 1 32
nadu gounder i12012440 75 1 1 1 1 1 0 1 0 0 0 0 1 20 231 336 325 8.3 139 39 44 92 46 1 32
nagaraj i12000841 44 1 1 1 0 0 0 1 0 0 0 1 12 107 112 148 6.8 114 71 27 74 62 1 4
nagaraj i120321706 48 1 1 0 0 0 0 0 1 0 1 36 200 185 256 6.7 145 142 35 132 63 1 22
nagoor i12007052 49 1 1 0 0 0 0 0 1 0 1 1 112 103 122 200 7.09 177 150 34 129 50 3 90
narayanan i12024807 51 1 1 1 0 0 0 0 1 0 0 1 1 50 352 222 248 11.7 185 175 45 125 69 1 44
nataraj i11020838 69 1 1 1 0 0 0 0 0 0 1 0 1 1 1 132 225 298 7.78 179 208 40 118 54 1 2
nataraj i11024796 51 1 1 1 1 1 1 0 0 0 1 2 1 1 120 115 114 158 7.89 187 205 32 122 60 1 10
padmarajan i11029438 59 1 1 1 1 1 1 1 0 1 0 0 1 8 1 136 149 149 245 6.78 161 130 24 101 60 3 124
padmavathi i12028216 75 1 1 1 1 0 1 0 0 1 10 1 66 151 144 200 6.45 224 325 36 186 57 2 66
palaanisamy i12029738 53 1 1 0 0 0 0 0 1 1 5 1 90 206 136 165 6.9 175 142 54 142 68 1 88
palaniappan i12005868 62 1 1 1 0 0 0 0 0 1 1 10 1 1 120 287 155 165 7.89 88 60 46 32 55 3 42
palanisamy 12004907 74 1 1 1 1 0 0 0 0 0 1 1 15 1 1 130 190 164 154 6.94 134 91 31 84 53 3 98
palanisamy i12023033 45 1 1 0 0 0 0 0 1 1 8 1 120 229 158 145 7.6 199 114 35 145 56 3 68
palanisamy i12024862 65 1 1 1 0 0 0 0 0 1 0 1 120 340 83 152 6.9 238 275 40 163 63 3 60
palanisamy i12030915 60 1 1 1 1 1 1 0 0 1 0 0 1 10 1 130 108 115 102 6.9 127 110 24 80 28 2 65
paramasivam i11020598 74 1 1 1 0 0 0 0 1 0 1 5 1 1 1 1 212 99 152 7.76 143 274 30 80 70 1 20
perumalsamy i12027701 67 1 1 1 0 0 0 0 1 0 0 1 132 102 76 99 7.1 180 142 32 130 68 3 90
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ponnusamy i11025931 45 1 1 1 1 0 0 1 0 0 0 1 1 50 122 111 148 6.98 163 121 24 116 62 1 32
poovai i12028198 58 1 1 0 0 0 0 0 1 1 2 1 120 147 142 175 7.5 196 136 32 147 60 1 35
prabhakaran i12014048 41 1 1 1 1 1 0 0 0 0 1 70 210 169 185 7.75 182 147 37 133 52 1 20
prabhakaran i12021525 52 1 1 1 0 0 0 0 1 0 0 1 1 1 189 105 208 7.35 118 81 28 79 71 3 48
prabhu i12009258 43 1 1 1 1 1 0 0 1 0 0 0 1 24 254 156 258 9.96 175 150 30 122 60 1 28
radhakrishnan i11022314 61 1 1 1 1 0 0 1 0 0 0 0 1 1 20 245 202 285 7.35 87 76 15 57 62 1 32
ragavan i12021356 45 1 1 1 1 0 1 0 0 0 0 1 1 1 1 412 197 206 12.7 227 256 43 155 58 1 16
raghu kumar i12013719 53 1 1 1 1 1 0 1 0 0 0 0 1 50 333 272 247 12.7 202 704 37 100 59 2 28
raj kumar i12020743 54 1 1 1 1 1 0 0 0 0 1 1 1 50 208 156 185 12.4 188 163 30 140 53 1 30
rajagopalan i12015053 71 1 1 1 1 1 1 0 0 1 0 0 0 1 1 1 1 62 96 99 108 6.71 164 98 42 107 53 2 42
rajamani i11023197 59 1 1 1 1 1 0 1 0 0 0 0 0 1 1 1 265 228 285 13.3 322 125 32 182 60 2 15
rajendran i12011507 55 1 1 1 0 1 0 0 0 0 1 3 1 120 188 129 165 6.7 204 93 47 153 45 1 80
rajendran i12027383 54 1 1 0 0 0 0 0 0 1 1 5 1 128 83 88 155 6.7 126 83 27 82 56 2 105
raju i12029503 45 1 1 1 1 1 0 0 0 0 0 1 40 199 102 125 6.67 196 335 28 112 55 1 10
ramaamoorthy i12020819 71 1 1 1 1 1 1 1 0 0 0 0 0 1 1 1 276 160 202 6.54 186 492 34 73 54 1 20
ramachandran i12032092 79 1 1 0 0 0 0 1 0 0 1 5 1 122 182 122 165 7.6 166 177 32 162 46 3 66
ramakrishnan i11021005 66 1 1 1 1 1 1 1 0 0 0 0 0 1 1 1 1 336 165 225 7.8 144 139 29 94 48 1 26
ramakrishnan i12021291 56 1 1 0 0 1 0 0 0 1 0 1 62 205 137 189 6.59 173 156 45 102 40 2 36
ramar i11031192 46 1 1 1 1 1 0 1 0 0 0 0 1 1 1 108 99 108 9.9 165 184 32 112 63 1 12
ramasamy i12006902 49 1 1 0 0 0 0 0 0 1 0 1 12 201 155 168 7.2 109 98 34 98 60 1 18
ramasamy i12015074 53 1 1 1 0 0 0 0 0 1 0 0 1 1 128 215 144 156 9.02 158 68 35 122 60 1 88
ranganathan i12004748 57 1 1 1 0 1 0 0 0 0 1 8 1 112 104 99 111 6 191 61 63 119 55 1 80
rangaraj i12014944 54 1 1 0 0 0 0 0 0 1 0 1 1 120 117 124 142 6.8 160 88 31 121 69 1 90
ravi i12000776 51 1 1 1 1 0 0 1 0 0 0 0 0 1 130 117 139 169 6.6 198 175 28 107 47 3 76
robert i11021108 33 1 1 1 1 0 1 0 0 0 0 0 1 1 1 1 181 175 148 6.4 230 55 49 178 66 1 38
samiyappan i12029460 47 1 1 1 0 1 0 0 0 0 1 5 1 1 1 169 133 145 8.81 256 154 46 194 69 1 26
sampathkumar i11034668 52 1 1 1 1 0 1 0 0 0 0 1 5 1 1 1 237 156 185 8.46 198 146 28 144 70 2 42
saravanan i12015358 37 1 1 0 0 0 0 0 0 1 0 1 1 1 90 99 122 7.5 152 178 35 102 79 1 20
seetharaman i12027779 58 1 1 0 0 0 0 0 0 1 0 1 1 44 113 114 136 8.2 245 158 29 164 70 2 44
sekar i12001166 41 1 1 1 0 0 0 0 0 0 1 0 1 1 1 257 162 200 9.11 251 546 28 144 70 3 52
selva rajan i12030681 64 1 1 1 1 0 0 1 0 0 0 0 1 1 100 205 165 185 6.6 205 41 33 122 60 2 80
selvaraj i11024264 43 1 1 1 0 0 0 0 0 0 1 1 8 1 40 114 110 145 7.7 167 122 22 124 80 2 34
selvaraj i11034171 61 1 1 0 0 0 0 0 1 0 1 5 1 22 77 88 135 6.9 198 181 32 134 66 2 16
selvaraj i11033528 66 1 1 0 0 0 0 0 1 0 1 5 1 1 1 135 110 165 7 174 108 30 122 66 1 22
selvaraj i11036200 53 1 1 0 0 0 1 0 0 0 0 1 130 119 137 140 8.2 175 152 37 110 69 3 88
selvaraj i12006512 47 1 1 1 1 1 0 0 0 0 0 1 1 1 230 148 185 7.1 206 156 40 196 50 3 38
selvaraj i12017742 46 1 1 1 1 1 1 0 0 1 0 0 0 1 4 1 1 108 245 216 201 9.87 215 184 30 161 40 1 90
selvaraj i12029693 52 1 1 1 1 p 1 0 0 0 0 0 1 127 399 344 320 9.7 179 82 41 117 45 1 102
sengotayan i12010856 59 1 1 1 1 1 0 0 0 0 0 1 1 80 108 98 100 6.8 142 108 25 110 55 2 35
seniappan i12020485 55 1 1 1 1 1 1 0 0 0 0 0 1 0 120 388 231 268 13.49 184 54 54 119 60 1 80
shanmugam.m i12000873 44 1 1 1 0 0 0 1 0 0 0 1 2 1 122 122 102 145 6.9 196 105 27 145 56 3 95
shanmugasundaram i12009419 55 1 1 1 1 1 0 0 0 0 1 2 1 1 100 203 146 202 6.2 175 120 35 169 50 2 85
sivabalan i12012491 59 1 1 1 0 0 0 1 0 0 1 1 5 1 1 1 160 142 178 6.45 227 67 47 172 49 3 38
sivakumar i12030079 55 1 1 1 0 0 0 0 0 1 0 1 2 1 36 174 94 132 7.2 127 160 31 68 63 1 20
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sivanandham i12028230 42 1 1 1 0 0 0 0 0 1 0 0 1 100 138 95 132 6.8 156 94 35 109 56 2 65
sivaraj i12023534 57 1 1 1 1 0 0 0 0 0 1 0 0 1 1 1 224 162 198 9.6 117 69 45 99 36 1 12
sivasubramaniam i12024169 52 1 1 1 0 1 0 0 0 0 0 1 56 299 271 225 8.27 203 242 49 134 73 1 35
soma sundaram i12024646 65 1 1 1 1 1 0 0 0 0 0 1 40 147 112 142 6.6 180 37 60 127 52 1 35
srinivasan i12030932 70 1 1 1 1 1 1 0 0 0 0 0 1 1 1 1 102 102 136 7.1 125 33 24 90 63 1 28
stephen i11024466 43 1 1 1 1 1 1 0 1 0 0 0 1 5 1 1 1 191 144 142 7.3 213 124 28 161 60 1 16
subramaniam i11023415 66 1 1 1 0 1 0 0 0 0 0 1 1 128 322 149 175 9.94 223 113 48 159 51 1 82
subramaniam i12001600 65 1 0 1 0 0 0 0 0 0 1 1 5 1 1 36 102 99 145 8.2 264 175 35 196 60 3 102
subramaniam i12030398 73 1 1 0 0 0 0 0 0 1 0 1 38 101 98 142 7.2 188 222 30 119 63 1 52
subramaniam i12030530 60 1 1 1 0 0 0 0 0 0 1 0 1 1 1 169 94 115 6.6 161 95 24 118 45 1 25
subramanian i12004016 57 1 1 1 1 1 1 1 0 1 0 0 0 1 4 1 1 68 188 118 169 6.9 220 117 52 144 50 2 66
subramanian.n i12001584 48 1 1 1 0 0 0 0 0 0 1 0 0 1 1 1 244 120 202 8.5 150 131 37 90 80 2 32
subramanianm i12012915 54 1 1 1 1 1 0 0 0 0 0 1 40 281 125 136 13.1 165 86 35 103 78 1 28
sukumaran i11033676 52 1 1 0 0 0 0 0 0 1 1 5 1 44 366 196 189 9.8 227 152 31 165 62 1 24
sulaiman i11030107 62 1 1 1 0 0 0 0 0 0 1 1 4 1 1 45 230 114 200 7.3 212 165 35 138 60 3 48
suraj i12021038 67 1 1 1 1 1 1 0 1 0 0 0 0 1 1 1 208 227 226 8.8 222 182 40 165 60 2 15
swaminathan i12005124 46 1 1 1 1 0 0 0 0 0 0 1 0 1 128 300 218 220 10 159 299 17 95 36 3 102
thamarai selvan i12024957 30 1 1 1 1 1 1 0 1 0 0 0 0 1 1 1 1 87 90 162 8.6 160 185 50 114 73 1 33
thangavelu i12001566 51 1 1 0 0 0 1 0 0 1 1 2 1 1 100 163 122 169 7.2 200 162 34 142 45 1 62
thangavelu i12000853 51 1 1 1 1 0 0 0 1 0 0 1 1 8 1 102 160 142 148 8.6 148 90 23 104 40 3 68
vairam i12001289 57 1 1 1 1 0 1 0 0 0 0 1 5 1 14 188 88 136 6.8 140 175 38 136 61 1 18
vaithyanathan i12015483 76 1 1 0 0 0 0 0 0 1 1 2 1 1 1 143 130 136 6.38 99 68 37 56 55 3 66
vauyapuri i12009520 52 1 1 1 1 0 1 0 0 0 0 1 5 1 1 8 146 103 222 6.6 148 120 29 106 55 1 14
veerasamy i12031696 73 1 1 1 1 0 1 0 0 0 0 1 1 1 1 120 216 188 266 9.6 290 194 49 215 25 2 27
velayutham i12015529 55 1 1 1 1 1 1 0 0 0 0 1 2 1 20 94 105 163 8.9 96 99 22 61 39 1 22
vellingiri i12019093 70 1 1 1 0 0 0 0 0 0 1 0 1 0 130 122 129 188 6.56 160 135 38 104 56 3 92
velumani i11031577 37 1 1 1 0 0 0 1 0 0 1 2 1 36 288 199 265 14.2 165 42 40 118 72 1 26
velusamy i12008041 63 1 1 1 0 1 0 0 0 0 0 1 1 1 285 205 265 10.4 138 91 49 78 45 2 48
velusamy i12015904 51 1 1 1 0 0 0 0 0 0 1 1 3 1 1 28 150 125 169 8.5 135 53 39 95 60 3 38
vengatesan i12017817 70 1 1 0 0 0 0 0 1 0 1 5 1 70 251 211 155 10.3 150 60 33 110 76 1 44
venkatachalam i11032378 68 1 1 1 0 0 0 0 0 0 1 1 5 1 130 322 200 265 10.7 168 113 24 124 68 3 136
venkatachalam i12005105 53 1 1 1 1 1 1 0 0 0 0 1 1 1 1 128 436 370 192 9.31 227 286 38 141 45 2 95
venkatasalam i12021906 45 1 1 1 0 0 0 0 0 0 1 1 10 1 1 1 224 200 266 7 138 76 45 98 56 1 12
vettal i12011943 57 1 1 0 0 0 0 0 0 1 0 1 1 1 121 99 105 7.4 265 175 42 182 75 1 28
vijay anand i12006220 34 1 1 1 1 1 1 0 0 0 0 0 1 1 1 365 149 175 10.4 203 168 30 140 60 1 35
vijayaraghavan i12018842 63 1 1 1 0 0 1 0 0 0 0 0 1 80 237 131 265 8.69 169 72 33 124 40 3 88
viyayakumar i12014441 32 1 1 1 1 0 1 0 0 0 0 1 1 1 305 235 266 8.96 146 94 28 112 56 2 44
amsaveni i12008248 55 0 1 1 0 1 0 0 0 0 0 1 1 98 96 132 5.5 145 70 41 102 65 1 42
amutha i11036004 56 0 1 1 1 1 0 0 1 0 0 0 0 1 0 0 0 98 88 142 5.68 188 80 34 152 46 1 35
bakkaiam i12029279 57 0 1 1 0 1 0 0 0 0 0 0 218 107 142 3.06 143 113 27 94 72 1 30
kasthuri i12006068 59 0 1 1 1 0 1 0 0 1 5 253 219 188 5.5 238 70 52 167 60 2 28
kulandayal i11021133 69 0 1 1 1 0 1 0 0 0 1 5 96 94 120 5.56 156 77 38 102 50 1 25
kumari i12017131 51 0 1 1 0 0 0 0 1 0 0 94 99 106 5.3 175 101 46 145 36 2 38
lalitha i11031725 57 0 1 0 0 0 0 1 0 1 3 86 91 124 5.3 209 74 46 148 69 1 20
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mylathal i12032121 50 0 1 1 0 0 0 0 1 0 1 4 100 95 129 5.52 142 62 45 100 56 1 22
pappa i12008392 43 0 1 1 1 0 1 0 0 0 0 145 108 128 5.5 114 42 45 62 30 3 5
pichiammal i12018281 50 0 1 1 0 1 0 0 0 0 130 98 125 5.6 206 111 49 113 50 1 6
ranganayaki i12029401 70 0 1 1 0 1 0 0 0 0 0 132 100 136 5.58 214 73 61 105 50 1 20
sargunam i11033097 64 0 1 1 1 p 0 0 1 0 0 0 1 1 140 107 148 5.1 154 119 23 110 68 1 42
saroja i12020608 42 0 1 1 1 1 1 0 0 0 0 1 2 177 141 145 4.9 193 150 34 145 42 1 32
savithri i11028530 38 0 1 1 0 0 0 0 0 1 0 0 94 98 175 5.6 193 109 36 125 68 1 16
sornam i12002260 61 0 1 1 1 1 1 1 0 0 0 0 0 147 140 142 5.3 219 108 41 141 49 1 18
viyayalakshmi i12014241 49 0 1 1 1 1 1 0 0 0 0 1 4 89 92 110 5.6 202 352 27 142 55 1 12
yaseen i11027892 39 0 1 1 1 0 1 0 0 0 0 99 99 142 5.4 237 61 38 176 50 2 88
ayyasamy i12024332 63 1 1 0 0 0 0 0 0 0 1 1 5 102 126 123 5.2 194 118 36 154 48 3 75
balakrishnan i12003421 58 1 1 1 0 1 0 0 0 0 0 0 182 124 125 5.45 220 316 32 144 61 1 102
balaraman i12000194 74 1 1 1 0 0 0 0 0 0 0 1 1 10 1 125 106 136 5.5 181 37 46 118 56 1 48
balu i12026630 55 1 1 1 1 1 1 1 0 0 0 0 0 1 3 102 91 108 178 101 29 140 30 1 90
cbinna karuppan i12004549 47 1 1 1 1 1 1 0 0 0 0 0 0 140 144 142 5.2 136 48 33 88 48 1 6
chandrasekaran i12033200 52 1 1 1 0 0 1 0 0 0 1 4 103 96 125 5.24 183 84 37 130 72 1 12
chinnaraja i11024110 53 1 1 1 1 1 1 0 0 1 0 0 0 0 0 1 129 92 135 5.4 151 97 23 116 62 3 28
dhandapani i11034508 45 1 1 1 1 0 1 0 0 0 0 0 0 88 99 125 5.5 158 84 32 106 42 1 16
edward i12016651 52 1 1 1 1 1 1 0 0 0 0 0 0 98 92 104 5.48 225 78 47 173 55 1 16
elaiyappan i12024107 65 1 1 1 0 1 0 0 0 0 0 0 108 104 185 5.6 159 144 25 126 51 2 80
ellumalai i11022874 41 1 1 0 1 0 0 0 0 0 0 1 119 96 165 5.3 176 132 29 120 67 1 22
gopal i12017714 48 1 1 1 1 1 1 0 0 0 0 0 0 1 132 96 134 5.1 152 125 42 95 52 2 22
gopal i12030042 60 1 1 1 1 1 0 1 0 0 0 0 0 106 99 124 5.15 165 152 25 142 42 2 45
gopalasamy i12011055 48 1 1 0 0 0 0 0 0 1 0 1 1 131 111 126 5.44 156 101 38 108 76 1 18
gopi i12028602 54 1 1 1 1 1 1 0 0 0 0 0 0 87 102 165 5.2 190 96 28 141 45 2 58
govindaraj i11022568 64 1 1 0 0 0 0 0 0 0 1 0 191 117 145 5.38 165 145 34 112 65 2 60
govindaraj i12018002 30 1 1 1 1 1 1 1 0 0 0 0 0 0 1 124 105 135 5.5 140 220 14 81 36 1 12
gurusamy i12019136 60 1 1 0 0 0 0 0 0 0 1 1 2 105 91 148 5.66 183 122 43 132 75 1 20
jagadeesan i12003041 66 1 1 0 0 0 0 0 0 0 1 0 100 75 105 5.6 147 58 44 93 53 1 8
jayakumar i12029770 42 1 1 1 0 0 1 0 0 0 0 0 98 101 136 5.45 153 128 41 87 53 1 4
jayaram i12008184 61 1 1 1 1 1 0 1 0 0 0 0 0 0 1 136 121 128 5.6 187 59 57 128 46 3 183
joseph i12014747 61 1 1 0 0 0 0 0 0 0 122 98 140 5.66 175 80 46 122 55 1 32
kanagaraj i11027303 51 1 1 1 1 0 1 0 0 0 99 89 136 5.4 148 229 29 76 70 1 16
kandasamy i12022316 70 1 1 1 0 0 0 1 0 1 1 5 98 96 185 5.2 176 168 35 165 50 1 36
kandhasamy i11024373 76 1 1 1 0 0 0 0 0 1 0 1 88 95 132 5.5 148 57 37 97 40 3 28
kandhasamy i12024514 41 1 1 1 0 0 0 0 0 1 0 125 95 142 5.5 153 238 32 93 54 1 12
kaniaapan i12011318 78 1 1 1 0 1 0 0 0 1 8 136 105 146 5 118 49 51 55 42 1 88
karuppusamy i12023887 42 1 1 1 1 0 1 0 0 0 0 231 108 142 5.38 197 151 40 140 58 1 12
kolaindaisamy i12014936 81 1 1 1 0 0 0 0 0 1 0 1 90 95 142 5.6 169 98 24 145 57 2 25
krishnasamy i12001823 70 1 1 1 0 0 0 0 0 1 0 1 113 101 136 5.55 189 195 24 165 50 1 12
krishnavelu i11030421 63 1 1 1 0 0 1 0 0 1 10 141 102 124 5.6 176 138 34 122 50 1 18
kumarasamy i11030241 50 1 1 1 1 1 0 0 0 1 1 114 98 108 5.4 312 345 22 145 42 3 46
kumarasamy i12000263 46 1 1 1 1 0 0 0 1 0 0 0 1 132 95 104 5.6 165 115 29 117 48 1 35
leoraj i11021565 63 1 1 1 1 0 0 1 0 0 0 89 81 136 5 123 77 30 75 50 1 38
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linganathan i11024022 56 1 1 1 1 p 0 1 0 0 0 203 100 142 5.3 169 45 35 122 45 1 66
malleswaran i12001209 23 1 1 1 1 0 0 1 0 0 0 0 83 90 105 5.4 185 175 29 159 70 1 8
mani i12029238 55 1 1 1 1 1 1 0 0 0 1 12 120 108 136 5.5 142 109 26 90 64 2 65
mani i120310164 68 1 1 1 0 1 0 0 0 0 81 71 105 5.4 126 89 33 74 67 1 14
manivannan i12001286 33 1 1 0 0 0 1 0 0 0 1 90 95 108 5.6 121 214 27 65 72 1 6
manivelsamy i110242320 61 1 1 1 1 1 1 0 0 0 0 116 92 112 5.47 102 109 30 51 77 1 22
manoharan i12002041 55 1 1 0 0 0 0 0 1 0 145 92 142 5.6 177 146 33 116 63 1 18
manoharan i12015281 54 1 1 1 1 1 1 0 0 0 0 1 114 93 135 5.24 149 120 39 98 47 1 60
marappan i12013776 56 1 1 1 1 1 0 0 0 1 1 1 103 92 128 5.8 165 126 36 140 71 1 28
marimuthu i12009488 79 1 1 1 1 1 1 0 0 0 0 140 120 136 5.64 168 57 51 115 60 1 18
marimuthu i12017998 34 1 1 1 1 1 0 0 0 0 99 92 172 5.46 231 175 34 162 60 1 16
marmuthu i12027952 49 1 1 1 1 0 0 0 0 0 0 95 98 136 5.1 146 105 42 125 50 2 20
muralishankar i11030377 50 1 1 1 1 0 1 0 0 0 0 104 95 132 5.3 183 62 33 137 55 3 154
murugesan i12015155 31 1 1 0 0 0 0 0 1 1 1 1 94 108 142 5.5 172 102 45 102 68 1 2.5
muthu i12013565 54 1 1 1 1 1 1 0 0 0 0 126 98 136 5.68 204 145 42 153 40 1 32
muthukumarasamy i11027188 49 1 1 0 0 1 0 0 1 1 2 1 92 94 122 5.29 143 101 24 94 66 1 15
nanjappan i12023689 68 1 1 1 0 0 1 0 0 1 1 5 102 89 125 5.6 168 88 42 142 72 1 28
nanjukutty i12021388 63 1 1 1 1 1 0 0 0 1 2 108 113 142 5.45 190 179 42 134 64 1 36
nataraj i11035124 67 1 1 1 0 1 0 0 0 1 1 107 95 136 5.4 95 94 29 44 60 1 32
natarajan i12001571 48 1 1 1 0 0 0 0 0 1 0 77 86 122 5.4 151 140 21 104 52 2 58
natrajan i12032699 72 1 1 1 1 1 0 1 0 0 0 99 88 99 5.5 162 63 37 115 46 1 32
palaniappan i11032481 71 1 1 1 0 0 0 0 1 0 0 89 110 104 5.34 154 51 40 102 88 3 188
palanimuthu i12022595 48 1 1 1 1 1 0 0 0 0 1 105 94 142 5.2 176 86 66 101 75 1 32
palanisamy i12013081 53 1 1 1 1 1 1 0 1 0 0 1 1 102 95 127 5.3 164 98 30 150 40 1 20
palanisamy i12027045 50 1 1 1 1 1 0 1 0 0 0 89 90 136 5.6 176 145 28 16 60 1 88
palanisamy.o i12004866 46 1 1 0 0 0 0 0 1 0 97 93 98 5.2 170 126 28 119 52 1 74
periyasamy i12008232 73 1 1 1 1 1 0 0 1 0 0 1 2 154 101 135 5.5 175 158 26 175 33 3 165
periyasamy i12025563 48 1 1 0 0 0 0 0 1 0 120 97 132 4.5 97 88 48 47 56 1 10
ponnusamy i12011198 37 1 1 1 1 0 1 0 0 0 126 123 152 5.4 125 70 37 78 58 2 55
ponnusamy i12029218 55 1 1 1 1 0 1 0 0 0 0 120 95 136 5.5 119 67 26 80 50 1 39
prakash i12005999 61 1 1 1 1 1 0 0 0 1 2 120 86 111 5.5 156 102 29 132 55 1 4
prakash i12017001 39 1 1 0 0 0 0 0 1 0 1 120 102 136 5.4 310 333 45 225 58 3 34
pramod i12027776 41 1 1 1 0 0 0 0 0 1 0 106 98 136 5.1 169 193 33 103 60 1 8
radhakrishnan i11020932 54 1 1 1 0 1 0 0 0 0 0 90 95 102 5.6 176 96 35 129 67 1 22
rajan i12021948 61 1 1 0 0 0 0 0 0 1 0 90 120 125 5.5 175 81 38 121 50 3 46
ramachandran i12018640 62 1 1 1 0 0 0 0 0 1 0 0 104 91 142 5.5 170 81 40 115 62 1 48
ramanathan i12004527 50 1 0 0 0 0 0 0 0 0 123 161 136 5.6 168 95 41 107 55 1 42
ranganathan i11024511 79 1 1 1 1 1 0 0 0 0 0 1 200 102 150 5.4 130 50 22 95 55 1 75
rangasamy i12004887 74 1 1 1 0 0 0 0 0 0 1 1 2 106 122 136 5.3 138 119 42 80 38 3 75
rangasamy i12013100 49 1 1 1 1 1 1 1 0 0 0 0 1 3 107 91 142 5.5 226 94 40 166 36 1 80
sakthivel i12000053 53 1 1 0 0 0 0 0 0 1 1 2 136 106 135 5.46 144 227 25 81 62 1 52
sakthivel i12012191 45 1 1 1 1 1 1 0 1 0 0 0 0 105 95 136 5.6 185 152 39 185 52 1 28
sam chelladurai i12002885 35 1 1 1 1 1 1 1 0 0 0 0 0 1 120 90 125 4.9 170 200 26 152 45 1 12
sastha i11032818 32 1 1 1 0 1 0 0 0 0 1 4 140 121 165 4.6 232 238 45 156 44 1 52
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sekar i11026168 59 1 1 1 1 1 0 1 0 0 0 1 2 1 89 95 140 5.5 153 85 25 119 60 1 26
selvaraj i12031078 35 1 1 0 0 0 0 0 0 1 0 122 101 135 5.3 242 145 36 168 65 1 18
senthil kumar i12007020 38 1 1 1 1 1 0 0 0 0 0 135 127 142 5.53 298 175 30 245 55 1 30
shanmugam i12001375 79 1 1 1 1 0 0 0 0 0 0 1 1 5 128 138 136 5.66 221 67 55 151 62 2 42
shanmugam i12017542 45 1 1 1 1 1 0 0 0 0 0 1 131 136 122 5.8 235 70 54 174 50 1 26
sivanandan i12009861 58 1 1 1 0 1 0 0 0 0 0 124 95 135 5.68 120 105 30 69 70 1 45
sivaprakasam i11033191 61 1 1 1 1 1 1 0 0 0 0 0 1 136 101 164 5.6 231 174 45 162 45 1 26
srinivasan i12021878 67 1 1 1 1 1 0 0 1 0 0 0 0 106 95 135 5.4 206 40 51 145 54 1 32
subramaniam i11021327 47 1 1 1 1 1 0 0 0 0 1 2 125 94 145 5.2 199 152 35 136 40 1 22
subramaniam i12023697 48 1 1 1 0 0 0 0 0 1 0 1 4 124 90 135 5.21 197 128 38 144 80 2 80
subramanian i11029838 66 1 1 0 0 0 0 0 1 0 1 5 183 1123 152 5.3 206 303 28 112 49 2 36
subramanianm i12013873 66 1 1 1 1 0 1 0 0 0 0 0 104 89 135 5.6 179 102 45 128 49 1 18
sundaram i12015425 64 1 1 1 0 1 0 0 0 0 1 1 1 98 88 102 5 129 84 35 89 76 1 28
sundaresan i12024293 56 1 1 1 1 0 0 1 0 0 0 0 121 126 136 5.6 146 103 52 90 63 1 18
thangavel i11025009 66 1 1 0 0 0 0 0 1 0 1 1 139 94 128 5.4 154 48 37 102 30 1 20
thangavel i11030157 57 1 1 0 0 0 0 0 1 0 0 117 88 136 5.65 152 103 38 105 60 1 26
thiyagarajan i12021239 30 1 1 1 1 1 1 0 0 0 0 0 1 121 111 145 5.6 183 111 41 102 60 1 5
vasantha kumar i12005891 42 1 1 1 1 0 1 0 0 0 0 0 165 122 125 5.55 220 526 33 109 48 2 11
velusamy i11025040 42 1 1 1 1 0 1 0 0 0 0 0 122 135 136 5.53 243 89 43 189 58 1 10
velusamy i11023872 70 1 1 0 0 0 0 0 0 1 0 1 100 98 108 5.5 132 100 35 102 60 1 18
velusamy i12033881 48 1 1 1 0 0 0 0 0 1 0 1 5 94 100 140 5.6 185 98 36 175 65 1 28
velusamy i12014956 74 1 1 1 1 1 1 1 0 0 0 0 0 1 216 98 135 5.6 236 119 49 183 40 3 48
velusamy i12023685 65 1 1 1 1 1 0 0 0 0 0 124 118 138 5.5 247 53 51 204 59 3 108
venkatakrishnan i11023380 61 1 1 1 1 1 1 0 0 0 0 0 1 128 120 145 5.68 137 75 39 84 44 3 54
vimalathithan i11022981 38 1 1 1 1 0 1 0 0 0 1 3 121 102 126 5.6 174 98 34 123 55 3 58
viswanathan i11035393 54 1 1 1 0 0 0 0 0 1 0 0 94 95 144 5.3 245 186 32 132 68 3 32
viswanathan i12025170 52 1 1 1 0 0 1 0 0 0 0 137 111 148 5.5 213 214 39 158 78 3 60
viswanathan i12026359 42 1 1 1 1 0 1 0 0 0 0 142 100 148 5.6 268 147 42 186 64 1 45
amsaveni i11021651 56 0 1 1 0 1 0 0 0 0 0 0 108 92 132 156 5.9 196 108 51 127 60 3 66
amuthavalli i12003298 50 0 1 1 1 0 1 0 0 0 0 0 1 1 136 98 123 142 5.97 116 86 39 69 56 1 30
junaimubakthat i12011577 54 0 1 1 0 0 0 0 0 1 1 2 142 101 149 135 6.2 192 85 46 175 53 1 48
kamalasarawathi i12003689 68 0 1 1 0 0 0 0 1 0 1 5 182 116 139 140 6.17 120 172 32 68 48 1 34
munirabegam i12009844 47 0 1 1 1 1 1 0 0 0 0 139 101 152 129 6.13 204 175 30 142 66 1 22
parvathy i12005960 54 0 1 0 0 0 0 0 1 0 159 114 160 156 5.97 391 134 51 310 50 1 15
roja mani i12001344 51 0 1 0 0 0 0 0 0 1 0 128 110 154 175 6.13 326 154 70 221 71 1 56
puspalatha i11030268 49 0 1 0 0 0 0 0 1 0 142 117 174 163 5.8 209 72 30 165 64 1 36
roja mani i12001344 51 0 1 0 0 0 0 0 0 1 0 128 110 154 175 6.13 326 154 70 221 71 1 56
saraswathy i12002558 63 0 1 1 1 0 1 0 0 0 0 0 163 118 185 138 6.1 256 185 34 121 65 1 20
subbathal i12001301 73 0 1 1 1 0 0 0 1 0 0 0 0 147 124 169 165 6.17 187 69 41 132 48 3 76
susila i12002891 50 0 1 1 0 0 0 0 0 0 1 0 111 122 148 128 6.13 123 308 50 223 66 1 24
vempayee i11020852 47 0 1 1 1 0 0 0 0 0 0 1 0 1 90 92 129 148 6 161 173 29 104 68 1 17
abdul rasheed i11032072 41 1 1 1 0 1 0 0 0 0 0 0 122 107 152 145 6.03 242 79 54 163 77 1 18
anbarasu i12002889 53 1 1 1 1 1 1 0 1 0 0 0 0 0 1 122 119 158 136 6.07 174 190 32 117 72 2 38
arumugam i1103583 64 1 1 1 1 p 1 0 0 0 0 0 0 125 125 167 185 6.39 108 59 27 69 75 1 35
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arumugam i12011589 52 1 1 1 0 0 0 0 0 0 0 1 0 145 120 167 164 5.8 136 47 32 105 68 1 18
balthasar i12007741 58 1 1 1 1 0 0 0 0 0 0 0 1 0 165 124 152 195 5.9 218 239 41 114 45 2 80
chinnasamy i12029662 58 1 1 1 0 0 1 0 0 0 0 0 145 117 137 175 5.79 189 135 32 139 45 2 110
damodaran i12012358 65 1 1 0 0 0 0 0 0 0 1 1 2 1 122 120 139 138 5.77 202 117 39 148 66 1 80
dayanand i12018528 39 1 1 1 1 0 0 1 0 0 0 0 0 105 95 128 148 5.72 184 150 42 124 75 1 38
dhandapani i12006932 55 1 1 1 1 0 0 0 0 1 0 0 0 124 109 139 144 5.85 224 182 47 152 42 2 4
duraisamy i12012754 71 1 1 0 0 0 0 0 0 0 1 1 5 154 121 158 150 5.96 125 85 29 85 59 3 58
farook i12012969 45 1 1 1 0 0 0 0 0 0 0 1 1 8 136 105 136 138 5.75 156 126 23 110 80 1 30
govindasamy i12028408 61 1 1 0 0 0 0 0 0 0 1 0 1 166 115 128 179 5.8 145 78 35 128 80 3 66
govindasamy` i120095026 56 1 1 1 0 0 0 0 0 0 0 1 0 128 116 136 150 6.2 129 68 33 91 65 1 18
jayapaul i11028570 56 1 1 1 1 0 0 1 0 0 0 0 165 129 142 139 6.29 166 105 24 120 66 3 65
kanagaraj i12030623 50 1 1 1 1 0 0 1 0 0 1 5 1 85 107 136 120 5.85 195 234 28 124 60 1 50
kandasamy i11027690 68 1 1 1 1 1 0 0 0 1 4 1 122 94 108 147 5.98 150 124 27 99 70 3 38
kittusamy i12009205 57 1 1 1 0 0 0 0 0 1 0 111 122 142 159 6.05 140 218 30 84 65 1 30
krishnan i12029082 60 1 1 1 1 1 1 0 0 0 0 115 110 138 126 5.8 222 254 35 155 49 2 32
krishnasamy i12032597 73 1 1 1 1 1 0 0 0 1 4 120 100 140 138 6.22 113 168 27 66 46 1 80
kumarasamy i12003671 68 1 1 1 1 0 1 0 0 0 124 96 118 141 6.25 145 108 28 106 50 1 8
kuppan i12030863 45 1 1 1 1 1 0 0 1 0 0 1 3 102 92 140 152 5.9 140 112 36 84 43 2 36
kuppusamy i12006437 61 1 1 1 0 0 0 0 1 0 1 2 130 116 148 168 5.7 189 99 57 121 62 1 32
leela krishnan i12020561 57 1 1 1 1 1 0 0 0 1 5 99 76 165 140 6.08 172 92 32 129 59 1 30
loganathan i12002296 39 1 0 0 0 0 1 0 0 1 125 99 113 136 6 337 273 19 265 70 1 28
malar mani nathan i12004802 43 1 1 1 1 1 0 1 0 0 0 166 125 166 174 5.96 185 185 28 132 58 1 21
mohamed ali i11024680 71 1 1 1 1 1 0 1 0 0 0 94 88 118 150 6.13 111 81 21 74 32 3 64
murugesan i11029109 65 1 1 0 0 0 0 0 1 0 157 118 169 199 6.1 145 120 34 106 71 1 78
muthusamy i11023259 54 1 1 1 1 1 0 0 0 0 1 119 115 157 180 6.1 159 60 33 113 72 1 74
muthusamy i12025161 64 1 1 1 1 0 0 1 0 0 1 5 189 113 149 164 5.8 219 51 49 182 30 3 55
nagaraj i11024318 43 1 1 1 p 0 1 0 0 1 4 188 122 154 166 5.8 209 76 50 136 52 1 102
natarajan i12006379 61 1 1 1 1 1 1 1 0 0 0 1 5 1 131 125 148 176 6.02 159 122 31 111 44 1 14
natesan i12027669 50 1 1 1 1 0 0 0 0 0 1 0 1 132 119 153 150 5.9 225 189 38 169 72 1 40
palanisamy i11028528 46 1 1 1 1 1 0 0 0 1 4 175 120 142 174 5.8 313 180 31 211 60 1 10
palanisamy i11035223 73 1 1 1 1 0 1 0 0 0 109 124 163 164 6.2 126 59 36 79 48 1 94
palanisamy i12002852 46 1 1 1 0 0 1 0 0 0 96 110 168 138 5.8 167 219 26 113 62 1 66
pradeep i12023550 47 1 1 1 1 1 1 0 0 0 0 148 105 147 162 5.8 215 115 35 158 65 3 40
rajendiran i12002581 39 1 1 0 0 0 0 0 0 1 0 1 104 107 149 182 6.1 148 220 37 102 40 2 30
raju i12001827 66 1 1 1 1 1 1 0 1 0 0 0 0 1 5 1 214 119 169 194 6.4 161 62 41 101 30 1 80
ram mohan i12000528 56 1 1 1 1 0 0 1 0 0 0 0 197 114 147 148 6 205 181 28 156 55 3 78
ramachandran i12004672 43 1 1 0 0 0 0 0 0 1 1 10 97 92 145 148 5.9 212 123 40 175 63 2 42
ramalingam i12007939 49 1 1 1 1 1 1 1 0 0 0 0 1 1 164 120 158 164 5.9 114 107 31 70 56 1 30
ramasamy i11028712 56 1 1 0 0 0 0 0 1 0 1 5 125 96 138 142 6 209 99 47 132 70 2 2
ramasamy i11029951 46 1 1 1 1 1 1 0 0 0 0 0 139 108 138 142 5.99 166 452 22 66 55 1 38
ramasamy i12003581 58 1 1 1 1 1 0 1 0 0 0 0 0 136 123 158 168 5.75 200 123 28 141 37 1 15
ranganathan i12006188 58 1 1 1 0 0 0 0 0 0 1 0 1 109 81 144 140 5.7 181 163 24 134 65 1 24
ranganathan i12016007 45 1 1 1 0 0 0 1 0 0 0 1 4 174 125 185 169 6.4 265 210 40 193 45 2 45
rangasamy i12007048 47 1 1 1 1 0 1 0 0 0 0 0 106 94 112 142 6.2 110 130 30 59 68 1 14
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rathinagiri i12016679 54 1 1 0 0 0 0 0 1 1 1 128 100 142 128 6.2 186 140 36 160 58 1 18
ravikumar i12007009 47 1 1 1 0 0 0 0 0 0 1 1 2 1 126 118 158 148 6 118 143 20 74 54 1 55
sathyamoorthi i12003450 39 1 1 1 1 1 0 0 0 0 0 125 98 172 144 5.67 155 169 34 90 65 1 25
seeniappan i12000383 65 1 1 1 1 0 0 0 0 0 1 0 1 5 128 99 166 165 6.35 175 85 28 149 70 3 86
selvaraj i11035800 51 1 1 1 p 0 1 0 0 0 0 136 96 148 136 6.3 183 84 35 135 71 1 88
shanmugasundaram i12003058 45 1 1 1 0 0 0 0 0 0 1 0 124 98 136 128 5.9 162 143 32 102 52 1 22
shanmugavel i11028471 61 1 1 1 0 0 0 0 0 1 0 136 120 162 175 6.04 161 72 41 94 74 2 35
shanmugavel i11030574 36 1 1 1 1 1 0 0 0 0 0 151 103 188 169 5.85 150 163 23 98 64 1 32
sivagnanma i12012472 43 1 0 0 0 0 0 0 1 0 1 128 114 147 155 6 125 48 35 81 66 32
subramani i12009459 64 1 1 1 1 1 0 0 0 0 0 1 112 109 155 168 6.05 111 103 36 59 40 1 36
subramaniam i12018447 43 1 1 1 1 1 0 0 1 0 0 0 0 1 122 100 150 147 5.8 100 237 47 147 72 2 56
swamippan i12024464 63 1 1 1 1 1 0 0 0 0 0 129 115 165 137 6.05 145 110 38 96 42 2 35
thirunavukarsu i12009097 47 1 1 1 1 1 0 1 0 0 0 1 1 147 119 175 148 5.78 197 215 35 136 40 3 38
ubidur rahman i12017332 55 1 1 1 0 1 0 0 0 0 0 136 91 136 140 5.8 115 201 26 65 72 1 28
velusamy i12009465 66 1 1 1 1 0 0 1 0 0 0 0 128 100 155 162 6.2 111 102 25 71 55 1 6
vincent i12006575 60 1 1 1 1 0 1 0 0 0 0 1 2 118 119 147 138 6.13 269 163 50 198 25 1 32

 
